<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        69-399-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VILTIN 50 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VILDAGLIPTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        66.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharma International Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 513]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI ARABIAN DRUG STORE COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:113.7pt; margin-right:0.1pt; text-align:left">The active substance of <strong>Viltin</strong><strong>&reg;</strong>, vildagliptin, belongs to a group of medicines called &ldquo;oral antidiabetics&rdquo;.</p><p style="margin-left:113.7pt; margin-right:-0.15pt; text-align:left; text-indent:-0.05pt"><strong>Viltin</strong><strong>&reg; </strong>is used to treat adult patients with type 2 diabetes. It is used when diabetes cannot be controlled by diet and exercise alone. It helps to control the level of sugar in the blood. Your doctor will prescribe <strong>Viltin</strong><strong>&reg; </strong>either alone or together with certain other antidiabetic medicines which you will already be taking, if these have not proved sufficiently effective to control diabetes.</p><p style="margin-left:113.7pt; margin-right:7.35pt; text-align:left">Type 2 diabetes develops if the body does not make enough insulin or if the insulin that the body makes does not work as well as it should. It can also develop if the body produces too much glucagon.</p><p style="margin-left:113.7pt; margin-right:10.25pt; text-align:left">Insulin is a substance which helps to lower the level of sugar in the blood, especially after meals.</p><p style="margin-left:113.7pt; text-align:left">Glucagon is a substance which triggers the production of sugar by the liver, causing the blood sugar level to rise. The pancreas makes both of these substances.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">How Viltin&reg; works</p><p style="margin-left:113.7pt; margin-right:-0.4pt; text-align:left"><strong>Viltin</strong><strong>&reg; </strong>works by making the pancreas produce more insulin and less glucagon. This helps to control the blood sugar level. This medicine has been shown to reduce blood sugar, which may help to prevent complications from your diabetes.</p><p style="margin-left:113.7pt; margin-right:5.55pt; text-align:left">Even though you are now starting a medicine for your diabetes, it is important that you continue to follow the diet and/or exercise which has been recommended for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:113.7pt; margin-right:0cm; text-align:left"><strong>Do not take Viltin</strong><strong>&reg;</strong><strong>:</strong></p><p style="margin-left:113.7pt; margin-right:0cm; text-align:left">&middot;<!--[endif]-->if you are allergic to vildagliptin or any of the other ingredients of this medicine. If you think you may be allergic to vildagliptin or any of the other ingredients of <strong>Viltin</strong><strong>&reg;</strong>, do not take this medicine and talk to your doctor.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Warnings and precautions</p><p style="text-align:left"><strong>Talk to your doctor, pharmacist or diabetes nurse before taking Viltin</strong><strong>&reg;</strong></p><p style="text-align:left">&middot;<!--[endif]-->If you have type 1 diabetes (i.e. your body does not produce insulin) or if you have a condition called diabetic ketoacidosis.</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->If you are taking an anti-diabetic medicine known as a sulphonylurea (your doctor may want to reduce your dose of the sulphonylurea when you take it together with <strong>Viltin</strong><strong>&reg; </strong>in order to avoid low blood glucose [hypoglycaemia]).</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->If you have moderate or severe kidney disease (you will need to take a lower dose of <strong>Viltin</strong><strong>&reg;</strong>).</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->If you are on dialysis.</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->If you have liver disease.</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->If you suffer from heart failure.</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->If you have or have had a disease of the pancreas.</p><p style="text-align:left">If you have previously taken vildagliptin but had to stop taking it because of liver disease, you should not take this medicine.</p><p style="text-align:left">Diabetic skin lesions are a common complication of diabetes. You are advised to follow the recommendations for skin and foot care that you are given by your doctor or nurse. You are also advised to pay particular attention to new onset of blisters or ulcers while taking <strong>Viltin</strong><strong>&reg;</strong>. Should these occur, you should promptly consult your doctor.</p><p style="text-align:left">A test to determine your liver function will be performed before the start of <strong>Viltin</strong><strong>&reg; </strong>treatment, at three month intervals for the first year and periodically thereafter. This is so that signs of increased liver enzymes can be detected as early as possible.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Children and adolescents</p><p style="margin-left:113.7pt; margin-right:0cm; text-align:left">The use of <strong>Viltin</strong><strong>&reg; </strong>in children and adolescents up to 18 years of age is not recommended.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Other medicines and Viltin&reg;</p><p style="margin-left:113.7pt; margin-right:0cm; text-align:left">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p style="margin-left:113.7pt; margin-right:7.35pt; text-align:left">Your doctor may wish to alter your dose of <strong>Viltin</strong><strong>&reg; </strong>if you are taking other medicines such as:</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Thiazides or other diuretics (also called water tablets).</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Corticosteroids (generally used to treat inflammation).</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Thyroid medicines.</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Certain medicines affecting the nervous system.</p><p style="text-align:left">Pregnancy and breast-feeding</p><p style="margin-left:113.7pt; margin-right:-0.95pt; text-align:left">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p style="margin-left:113.7pt; text-align:left">You should not use <strong>Viltin</strong><strong>&reg; </strong>during pregnancy.</p><p style="margin-left:113.7pt; margin-right:2.7pt; text-align:left">It is not known if vildagliptin passes into breast milk. You should not use <strong>Viltin</strong><strong>&reg; </strong>if you are breast-feeding or plan to breast-feed.</p><p style="text-align:left">Driving and using machines</p><p style="margin-left:113.7pt; margin-right:0cm; text-align:left">If you feel dizzy while taking <strong>Viltin</strong><strong>&reg;</strong>, do not drive or use machines.</p><p style="text-align:left">Viltin&reg; contains lactose</p><p style="margin-left:113.7pt; margin-right:2.7pt; text-align:left"><strong>Viltin</strong><strong>&reg; </strong>contains lactose (milk sugar). If you have been told by your doctor that you have an</p><p style="margin-left:113.7pt; text-align:left">intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:113.7pt; margin-right:-0.05pt; text-align:left">Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p style="text-align:left">How much to take and when</p><p style="margin-left:113.7pt; margin-right:0.15pt; text-align:left; text-indent:-0.05pt">The amount of <strong>Viltin</strong><strong>&reg; </strong>people have to take varies depending on their condition. Your doctor will tell you exactly how many tablets of <strong>Viltin</strong><strong>&reg; </strong>to take. The maximum daily dose is 100 mg.</p><p style="margin-left:113.7pt; text-align:left">The usual dose of <strong>Viltin</strong><strong>&reg; </strong>is either:</p><p style="margin-left:113.7pt; margin-right:10.35pt; text-align:left; text-indent:-0.05pt"><!--[if !supportLists]-->&middot;<!--[endif]-->50 mg daily taken as one dose in the morning if you are taking <strong>Viltin</strong><strong>&reg; </strong>with another medicine called a sulphonylurea.</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->100 mg daily taken as 50 mg in the morning and 50 mg in the evening if you are taking</p><p style="margin-left:113.7pt; margin-right:1pt; text-align:left"><strong>Viltin</strong><strong>&reg; </strong>alone, with another medicine called metformin or a glitazone, with a combination of metformin and a sulphonylurea, or with insulin.</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->50 mg daily in the morning if you have moderate or severe kidney disease or if you are</p><p style="margin-left:113.7pt; margin-right:0cm; text-align:left">on dialysis.</p><p style="text-align:left">How to take Viltin&reg;</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Swallow the tablets whole with some water.</p><p style="text-align:left">How long to take Viltin&reg;</p><p style="margin-left:113.7pt; margin-right:6.35pt; text-align:left; text-indent:0cm"><!--[if !supportLists]-->&middot;<!--[endif]-->Take <strong>Viltin</strong><strong>&reg; </strong>every day for as long as your doctor tells you. You may have to take this treatment over a long period of time.</p><p style="text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Your doctor will regularly monitor your condition to check that the treatment is having</p><p style="margin-left:113.7pt; margin-right:0cm; text-align:left">the desired effect.</p><p style="text-align:left">If you take more Viltin&reg; than you should</p><p style="margin-left:8.8pt; margin-right:119.25pt; text-align:left; text-indent:-0.05pt">If you take too many <strong>Viltin</strong><strong>&reg; </strong>tablets, or if someone else has taken your medicine, talk to your doctor straight away. Medical attention may be needed. If you need to see a doctor or go to the hospital, take the pack with you.</p><p style="text-align:left">If you forget to take Viltin&reg;</p><p style="margin-left:8.8pt; margin-right:116.2pt; text-align:left">If you forget to take a dose of this medicine, take it as soon as you remember. Then take your next dose at the usual time. If it is almost time for your next dose, skip the dose you missed. Do not take a double dose to make up for a forgotten tablet.</p><p style="text-align:left">If you stop taking Viltin&reg;</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left">Do not stop taking <strong>Viltin</strong><strong>&reg; </strong>unless your doctor tells you to.</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left">If you have questions about how long to take this medicine, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:8.8pt; margin-right:124.15pt; text-align:left">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="text-align:left">Some symptoms need immediate medical attention:</p><p style="margin-left:8.8pt; margin-right:122.25pt; text-align:left">You should stop taking <strong>Viltin</strong><strong>&reg; </strong>and see your doctor immediately if you experience the following side effects:</p><p style="margin-left:11.7pt; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Angioedema (rare: may affect up to 1 in 1,000 people): Symptoms include swollen face,</p><p style="margin-left:8.8pt; margin-right:105.7pt; text-align:left">tongue or throat, difficulty swallowing, difficulties breathing, sudden onset rash or hives, which may indicate a reaction called &ldquo;angioedema&rdquo;.</p><p style="margin-left:11.7pt; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Liver disease (hepatitis) (rare): Symptoms include yellow skin and eyes, nausea, loss of</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left">appetite or dark-coloured urine, which may indicate liver disease (hepatitis).</p><p style="margin-left:8.8pt; margin-right:118.75pt; text-align:left; text-indent:0cm"><!--[if !supportLists]-->&middot; <!--[endif]-->Inflammation of the pancreas (pancreatitis) (frequency not known): Symptoms include severe and persistent pain in the abdomen (stomach area), which might reach through to your back, as well as nausea and vomiting.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Other side effects</p><p style="margin-left:8.8pt; margin-right:135.9pt; text-align:left">Some patients have had the following side effects while taking vildagliptin and metformin:</p><p style="margin-left:11.7pt; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Common (may affect up to 1 in 10 people): Trembling, headache, dizziness, nausea,</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left">low blood glucose.</p><p style="margin-left:11.7pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Uncommon (may affect up to 1 in 100 people): Tiredness.</p><p style="margin-left:8.8pt; margin-right:132.45pt; text-align:left">Some patients have had the following side effects while taking vildagliptin and a sulphonylurea:</p><p style="margin-left:11.7pt; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Common: Trembling, headache, dizziness, weakness, low blood glucose.</p><p style="margin-left:11.7pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Uncommon: Constipation.</p><p style="margin-left:11.7pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Very rare (may affect up to 1 in 10,000 people): Sore throat, runny nose.</p><p style="margin-left:8.8pt; margin-right:132.45pt; text-align:left">Some patients have had the following side effects while taking vildagliptin and a glitazone:</p><p style="margin-left:11.7pt; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Common: Weight increase, swollen hands, ankle or feet (oedema).</p><p style="margin-left:11.7pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Uncommon: Headache, weakness, low blood glucose.</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left">Some patients have had the following side effects while taking vildagliptin alone:</p><p style="margin-left:11.7pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Common: Dizziness.</p><p style="margin-left:8.8pt; margin-right:117.7pt; text-align:left; text-indent:0cm"><!--[if !supportLists]-->&middot; <!--[endif]-->Uncommon: Headache, constipation, swollen hands, ankle or feet (oedema), joint pain, low blood glucose.</p><p style="margin-left:11.7pt; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Very rare: Sore throat, runny nose, fever.</p><p style="margin-left:8.8pt; margin-right:120.8pt; text-align:left">Some patients have had the following side effects while taking vildagliptin, metformin and a sulphonylurea:</p><p style="margin-left:11.7pt; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Common: Dizziness, tremor, weakness, low blood glucose, excessive sweating.</p><p style="margin-left:8.8pt; margin-right:121.05pt; text-align:left">Some patients have had the following side effects while taking vildagliptin and insulin (with or without metformin):</p><p style="margin-left:11.7pt; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Common: Headache, chills, nausea (feeling sick), low blood glucose, heartburn.</p><p style="margin-left:11.7pt; margin-right:0cm; text-align:left"><!--[if !supportLists]-->&middot; <!--[endif]-->Uncommon: Diarrhea, flatulence.</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left">Since vildagliptin has been marketed, the following side effects have also been reported:</p><p style="margin-left:8.8pt; margin-right:133.1pt; text-align:left; text-indent:0cm"><!--[if !supportLists]-->&middot; <!--[endif]-->Frequency not known (cannot be estimated from the available data): Itchy rash, inflammation of the pancreas, localised peeling of skin or blisters, muscle pain.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">If any of the side effects get serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:8.8pt; margin-right:0cm; text-align:left">Keep out of the reach and sight of children.</p><p style="margin-left:8.8pt; margin-right:127.7pt; text-align:left; text-indent:-0.05pt">Do not use <strong>Viltin</strong><strong>&reg; </strong>after the expiry date (EXP) which is stated on the blister and the carton.</p><p style="margin-left:8.8pt; text-align:left">The expiry date refers to the last day of that month.</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left"><strong>Viltin</strong><strong>&reg; </strong>tablets: Store below 30&deg;C.</p><p style="margin-left:8.8pt; margin-right:117.45pt; text-align:left">Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:8.8pt; text-align:left">The active substance is Vildagliptin.</p><p style="margin-left:8.8pt; margin-right:122.35pt; text-align:left">The other ingredients are anhydrous lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Viltin® 50 mg Tablets
White to off white oblong normal biconvex tablet engraved with PhI on one face, packed in Alu/Alu blister, intended for oral use.

Pack size:
7 tablets in Alu/Alu blister. 4 blisters/pack. 10 tablets in Alu/Alu blister. 6 blisters/pack.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:8.8pt; margin-right:231.3pt; text-align:left">Pharma International Company Amman - Jordan</p><p style="margin-left:8.8pt; text-align:left">Tel: 00962-6-5158890 / 5157893</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left">Fax: 00962-6-5154753</p><p style="margin-left:8.8pt; margin-right:0cm; text-align:left">Email: marketing@pic-jo.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 09/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">المادة&nbsp;الفعالة&nbsp;في&nbsp;فيلتين،&nbsp;هي&nbsp;فيلداجلبتين،&nbsp;التي&nbsp;تنتمي&nbsp;إلى&nbsp;مجموعة&nbsp;من&nbsp;الأدوية&nbsp;تعرف&nbsp;بمضادات&nbsp;داء&nbsp;السكري</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">التي&nbsp;يتم&nbsp;تناولها&nbsp;عن&nbsp;طريق&nbsp;الفم.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يستعمل&nbsp;فيلتينة&nbsp;لعلاج&nbsp;المرضى&nbsp;البالغين&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;النوع&nbsp;الثاني&nbsp;من&nbsp;داء&nbsp;السكري.&nbsp;يتم&nbsp;استعماله&nbsp;عندما</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">لا&nbsp;يمكن&nbsp;السيطرة&nbsp;على&nbsp;داء&nbsp;السكري&nbsp;عن&nbsp;طريق&nbsp;اتباع&nbsp;نظام&nbsp;غذائي&nbsp;وممارسة&nbsp;التمارين&nbsp;الرياضية&nbsp;فقط.&nbsp;يساعد&nbsp;في</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">السيطرة&nbsp;على&nbsp;مستوى&nbsp;السكر&nbsp;في&nbsp;الدم.&nbsp;سيصف&nbsp;الطبيب&nbsp;قيلتينه&nbsp;إما&nbsp;لوحده&nbsp;أو&nbsp;بالتزامن&nbsp;مع&nbsp;أدوية&nbsp;معينة&nbsp;أخرى</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">مضادة&nbsp;لداء&nbsp;السكري&nbsp;تتناولها&nbsp;حاليا،&nbsp;إذا&nbsp;لم&nbsp;تثبت&nbsp;هذه&nbsp;الأدوية&nbsp;فعاليتها&nbsp;في&nbsp;السيطرة&nbsp;على&nbsp;داء&nbsp;السكري&nbsp;بشكل&nbsp;كاف.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يحدث&nbsp;النوع&nbsp;الثاني&nbsp;من&nbsp;داء&nbsp;السكري&nbsp;عن&nbsp;عدم&nbsp;إنتاج&nbsp;الجسم&nbsp;كمية&nbsp;كافية&nbsp;من&nbsp;الإنسولين&nbsp;أو&nbsp;إذا&nbsp;كان&nbsp;الإنسولين&nbsp;الذي</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">ينتجه&nbsp;الجسم&nbsp;لا&nbsp;يعمل&nbsp;كما&nbsp;يجب.&nbsp;ومن&nbsp;الممكن&nbsp;أيضا&nbsp;أن&nbsp;يحدث&nbsp;بسبب&nbsp;إنتاج&nbsp;الجسم&nbsp;كمية&nbsp;كبيرة&nbsp;من&nbsp;جلوكاجون.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الإنسولين&nbsp;هو&nbsp;عبارة&nbsp;عن&nbsp;مادة&nbsp;تساعد&nbsp;في&nbsp;خفض&nbsp;مستوى&nbsp;السكر&nbsp;في&nbsp;الدم،&nbsp;خصوصا&nbsp;بعد&nbsp;الوجبات</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الجلوكاجون&nbsp;هو&nbsp;عبارة&nbsp;عن&nbsp;مادة&nbsp;تحفز&nbsp;الكبد&nbsp;على&nbsp;إنتاج&nbsp;السكر،&nbsp;مما&nbsp;يؤدي&nbsp;إلى&nbsp;ارتفاع&nbsp;مستوى&nbsp;السكر&nbsp;في&nbsp;الدم.&nbsp;يتم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إنتاج&nbsp;كلاهما&nbsp;في&nbsp;البنكرياس.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">كيفية&nbsp;عمل&nbsp;قيلتين*</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يعمل&nbsp;قيلتين&nbsp;عن&nbsp;طريق&nbsp;تحفيز&nbsp;البنكرياس&nbsp;الإنتاج&nbsp;كمية&nbsp;أكبر&nbsp;من&nbsp;الإنسولين&nbsp;وكمية&nbsp;أقل&nbsp;من&nbsp;الجلوكاجون.&nbsp;وهذا</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يساعد&nbsp;في&nbsp;السيطرة&nbsp;على&nbsp;مستوى&nbsp;السكر&nbsp;في&nbsp;الدم.&nbsp;أظهر&nbsp;هذا&nbsp;الدواء&nbsp;قدرته&nbsp;على&nbsp;خفض&nbsp;مستوى&nbsp;السكر&nbsp;في&nbsp;الدم،</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">وبالتالي&nbsp;قد&nbsp;يساعد&nbsp;في&nbsp;منع&nbsp;حدوث&nbsp;المضاعفات&nbsp;الناتجة&nbsp;عن&nbsp;داء&nbsp;السكري.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">من&nbsp;المهم&nbsp;الاستمرار&nbsp;باتباع&nbsp;نظام&nbsp;غذائي&nbsp;و/أو&nbsp;ممارسة&nbsp;التمارين&nbsp;الرياضة&nbsp;الموصى&nbsp;بها&nbsp;حتى&nbsp;وإن&nbsp;بدأت&nbsp;بتناول</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">دواء&nbsp;لعلاج&nbsp;داء&nbsp;السكري..</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">كيفية&nbsp;عمل&nbsp;فيلتين</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يعمل&nbsp;فيلتين&nbsp;عن&nbsp;طريق&nbsp;تحفيز&nbsp;البنكرياس&nbsp;لإنتاج&nbsp;كمية&nbsp;أكبر&nbsp;من&nbsp;الإنسولين&nbsp;وكمية&nbsp;أقل&nbsp;من&nbsp;الجلوكاجون.&nbsp;وهذا</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يساعد&nbsp;في&nbsp;السيطرة&nbsp;على&nbsp;مستوى&nbsp;السكر&nbsp;في&nbsp;الدم.&nbsp;أظهر&nbsp;هذا&nbsp;الدواء&nbsp;قدرته&nbsp;على&nbsp;خفض&nbsp;مستوى&nbsp;السكر&nbsp;في&nbsp;الدم،</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">وبالتالي&nbsp;قد&nbsp;يساعد&nbsp;في&nbsp;منع&nbsp;حدوث&nbsp;المضاعفات&nbsp;الناتجة&nbsp;عن&nbsp;داء&nbsp;السكري.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">من&nbsp;المهم&nbsp;الاستمرار&nbsp;باتباع&nbsp;نظام&nbsp;غذائي&nbsp;و/أو&nbsp;ممارسة&nbsp;التمارين&nbsp;الرياضة&nbsp;الموصى&nbsp;بها&nbsp;حتى&nbsp;وإن&nbsp;بدات&nbsp;بتناول</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">دواء&nbsp;لعلاج&nbsp;داء&nbsp;السكري.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">قبل&nbsp;أن&nbsp;تأخذ&nbsp;فيلتين&nbsp;أقراص</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الحالات&nbsp;التي&nbsp;يجب&nbsp;أن&nbsp;لا&nbsp;تأخذ&nbsp;فيها&nbsp;فيلتين&nbsp;أقراص:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;تحسس&nbsp;لفيلداجلبتين&nbsp;أو&nbsp;لأي&nbsp;من&nbsp;المكونات&nbsp;الأخرى&nbsp;في&nbsp;هذا&nbsp;الدواء.&nbsp;إذا&nbsp;كنت&nbsp;تعتقد&nbsp;أنك&nbsp;قد</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تعاني&nbsp;من&nbsp;تحسس&nbsp;لفيلداجلبتين&nbsp;أو&nbsp;لأي&nbsp;من&nbsp;المكونات&nbsp;الأخرى&nbsp;في&nbsp;فيلتين،&nbsp;لا&nbsp;تتناول&nbsp;هذا&nbsp;الدواء&nbsp;و&nbsp;تحدث&nbsp;مع</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">طبيبك</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الاحتياطات&nbsp;والمحاذير</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تحدث&nbsp;إلى&nbsp;الطبيب،&nbsp;الصيدلي&nbsp;أو&nbsp;الممرض&nbsp;المختص&nbsp;بداء&nbsp;السكري&nbsp;قبل&nbsp;تناول&nbsp;فيلتين&nbsp;في&nbsp;الحالات&nbsp;التالية:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;النوع&nbsp;الأول&nbsp;من&nbsp;داء&nbsp;السكري&nbsp;(أي&nbsp;أن&nbsp;الجسم&nbsp;لا&nbsp;ينتج&nbsp;الإنسولين)&nbsp;أو&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;حالة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تعرف&nbsp;بالحماض&nbsp;الكيتوني&nbsp;السكري.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;إذا&nbsp;كنت&nbsp;تتناول&nbsp;دواء&nbsp;مضاد&nbsp;لداء&nbsp;السكري&nbsp;يعرف&nbsp;بسلفونيل&nbsp;يوريا&nbsp;(قد&nbsp;يخفض&nbsp;الطبيب&nbsp;جرعتك&nbsp;من&nbsp;سلفونیل</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يوريا&nbsp;عند&nbsp;تناوله&nbsp;بالتزامن&nbsp;مع&nbsp;فيلتين&nbsp;و&nbsp;ذلك&nbsp;لتجنب&nbsp;انخفاض&nbsp;مستوى&nbsp;الجلوكوز&nbsp;في&nbsp;الدم).</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;مرض&nbsp;متوسط&nbsp;أو&nbsp;حاد&nbsp;في&nbsp;الكلى&nbsp;(ستحتاج&nbsp;إلى&nbsp;تناول&nbsp;جرعة&nbsp;أقل&nbsp;من&nbsp;فيلتين).</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;كنت&nbsp;تخضع&nbsp;للديلزة&nbsp;دموية.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;مرض&nbsp;في&nbsp;الكبد.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;قصور&nbsp;وظيفة&nbsp;عضلة&nbsp;القلب</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;أو&nbsp;عانيت&nbsp;في&nbsp;السابق&nbsp;من&nbsp;مرض&nbsp;في&nbsp;البنكرياس.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يجب&nbsp;عدم&nbsp;تناول&nbsp;هذا&nbsp;الدواء&nbsp;إذا&nbsp;قمت&nbsp;بتناول&nbsp;فيلد&nbsp;البتين&nbsp;في&nbsp;السابق&nbsp;و&nbsp;توقف&nbsp;عن&nbsp;تناوله&nbsp;بسبب&nbsp;وجود&nbsp;مرض&nbsp;في</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الكبد</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تعد&nbsp;آفات&nbsp;الجلد&nbsp;الناتجة&nbsp;عن&nbsp;داء&nbsp;السكري&nbsp;أحد&nbsp;المضاعفات&nbsp;الشائعة&nbsp;لداء&nbsp;السكري.&nbsp;ينصح&nbsp;باتباع&nbsp;التوصيات&nbsp;المتعلقة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">بالعناية&nbsp;بالجلد&nbsp;و&nbsp;القدم&nbsp;التي&nbsp;تعطي&nbsp;من&nbsp;قبل&nbsp;الطبيب&nbsp;أو&nbsp;الممرض.&nbsp;ينصح&nbsp;أيضا&nbsp;بالانتباه&nbsp;بشكل&nbsp;خاص&nbsp;لبدء&nbsp;ظهور</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">التنفطات&nbsp;أو&nbsp;التقرحات&nbsp;الجديدة&nbsp;خلال&nbsp;فترة&nbsp;تناول&nbsp;فيلتين&nbsp;يجب&nbsp;عليك&nbsp;استشارة&nbsp;طبيبك&nbsp;عند&nbsp;حدوث&nbsp;ذلك.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">سيقوم&nbsp;الطبيب&nbsp;بعمل&nbsp;فحوصات&nbsp;لوظيفة&nbsp;الكبد&nbsp;قبل&nbsp;بدء&nbsp;العلاج&nbsp;بفيلتين&nbsp;،&nbsp;و&nbsp;أيضا&nbsp;كل&nbsp;ثلاثة&nbsp;شهور&nbsp;خلال&nbsp;السنة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الأولى&nbsp;و&nbsp;بشكل&nbsp;دوري&nbsp;بعد&nbsp;ذلك.&nbsp;وذلك&nbsp;للكشف&nbsp;عن&nbsp;علامات&nbsp;زيادة&nbsp;إنزيمات&nbsp;الكبد&nbsp;في&nbsp;اقرب&nbsp;وقت&nbsp;ممكن</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الأطفال&nbsp;والمراهقون</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">لا&nbsp;يوصى&nbsp;باستعمال&nbsp;فيلتين&nbsp;للأطفال&nbsp;والمراهقين&nbsp;الذين&nbsp;تبلغ&nbsp;أعمارهم&nbsp;18&nbsp;عاما&nbsp;أو&nbsp;أقل.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تناول&nbsp;أدوية&nbsp;أخرى&nbsp;مع&nbsp;فيلتين</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">أخبر&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;إذا&nbsp;كنت&nbsp;تتناول،&nbsp;تناولت&nbsp;مؤخرا&nbsp;أو&nbsp;من&nbsp;الممكن&nbsp;أن&nbsp;تتناول&nbsp;أي&nbsp;أدوية&nbsp;أخرى.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">قد&nbsp;يعدل&nbsp;الطبيب&nbsp;جرعة&nbsp;فيلتين&nbsp;إذا&nbsp;كنت&nbsp;تتناول&nbsp;أدوية&nbsp;أخرى&nbsp;مثل:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;ثيازايد&nbsp;أو&nbsp;مدرات&nbsp;أخرى&nbsp;للبول</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull;&nbsp;الستيرويدات&nbsp;القشرية&nbsp;(تستعمل&nbsp;بشكل&nbsp;عام&nbsp;لعلاج&nbsp;الالتهاب).</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;أدوية&nbsp;الغدة&nbsp;الدرقية.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;أدوية&nbsp;معينة&nbsp;تؤثر&nbsp;على&nbsp;الجهاز&nbsp;العصبي.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الحمل&nbsp;و&nbsp;الرضاعة&nbsp;الطبيعية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;كنت&nbsp;حامل&nbsp;أو&nbsp;ترضعين،&nbsp;أو&nbsp;تعتقدين&nbsp;بانك&nbsp;حامل&nbsp;أو&nbsp;تخططين&nbsp;للحمل،&nbsp;استشيري&nbsp;الطبيب&nbsp;أو&nbsp;الصيدلي&nbsp;قبل</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تناول&nbsp;هذا&nbsp;الدواء</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يجب&nbsp;عدم&nbsp;تناول&nbsp;فيلتين&nbsp;خلال&nbsp;فترة&nbsp;الحمل.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">من&nbsp;غير&nbsp;المعروف&nbsp;ما&nbsp;إذا&nbsp;كان&nbsp;فيلداجلبتين&nbsp;يفرز&nbsp;في&nbsp;حليب&nbsp;الثدي.&nbsp;يجب&nbsp;عدم&nbsp;استعمال&nbsp;فيلتين&nbsp;إذا&nbsp;كنت&nbsp;ترضعين</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">أو&nbsp;تخططين&nbsp;للرضاعة&nbsp;الطبيعية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">القيادة&nbsp;و&nbsp;استخدام&nbsp;الآلات</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;شعرت&nbsp;بالدوار&nbsp;خلال&nbsp;فترة&nbsp;تناول&nbsp;فيلتين،&nbsp;تجنب&nbsp;القيادة&nbsp;أو&nbsp;استخدام&nbsp;الألات.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يحتوي&nbsp;فيلتين&nbsp;على&nbsp;اللاكتوز</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يحتوي&nbsp;فيلتين&nbsp;على&nbsp;اللاكتوز&nbsp;(سكر&nbsp;الحليب).&nbsp;إذا&nbsp;أخبرك&nbsp;طبيبك&nbsp;بأنك&nbsp;لا&nbsp;تستطيع&nbsp;تحمل&nbsp;بعض&nbsp;أنواع&nbsp;السكريات،</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">اتصل&nbsp;مع&nbsp;الطبيب&nbsp;قبل&nbsp;تناول&nbsp;هذا&nbsp;الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تناول&nbsp;هذا&nbsp;الدواء&nbsp;دائما&nbsp;كما&nbsp;أخبرك&nbsp;طبيبك.&nbsp;يجب&nbsp;عليك&nbsp;التحقق&nbsp;من&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;إذا&nbsp;لم&nbsp;تكن&nbsp;متأكدا&nbsp;من&nbsp;كيفية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">استخدام&nbsp;الدواء.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">جرعة&nbsp;فيلتين&nbsp;و&nbsp;وقت&nbsp;تناولها</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تختلف&nbsp;جرعة&nbsp;فيلتين&nbsp;الواجب&nbsp;تناولها&nbsp;اعتمادا&nbsp;على&nbsp;الحالة&nbsp;سيخبرك&nbsp;الطبيب&nbsp;بدقة&nbsp;عن&nbsp;الجرعة&nbsp;التي&nbsp;ستتناولها&nbsp;من</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">فيلتين.&nbsp;الجرعة&nbsp;اليومية&nbsp;القصوى&nbsp;هي&nbsp;100&nbsp;ملغم.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الجرعة&nbsp;المعتادة&nbsp;من&nbsp;فيلتين&nbsp;إما:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull; 50&nbsp;ملغم&nbsp;يتم&nbsp;تناولها&nbsp;يوميا&nbsp;كجرعة&nbsp;واحدة&nbsp;في&nbsp;الصباح&nbsp;إذا&nbsp;كنت&nbsp;تتناول&nbsp;فيلتين&nbsp;بالتزامن&nbsp;مع&nbsp;دواء&nbsp;آخر&nbsp;يعرف</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">بسلفونيل&nbsp;يوريا.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull; 100&nbsp;ملغم&nbsp;يتم&nbsp;تناولها&nbsp;يوميا&nbsp;50&nbsp;ملغم&nbsp;في&nbsp;الصباح&nbsp;و&nbsp;50&nbsp;ملغم&nbsp;في&nbsp;المساء&nbsp;إذا&nbsp;كنت&nbsp;تتناول&nbsp;فيلتين&nbsp;لوحده،&nbsp;أو</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">بالتزامن&nbsp;مع&nbsp;دواء&nbsp;آخر&nbsp;يعرف&nbsp;بميتفورمين&nbsp;أو&nbsp;جليتازون،&nbsp;أو&nbsp;بالتزامن&nbsp;مع&nbsp;دواء&nbsp;مركب&nbsp;من&nbsp;الميتفورمین&nbsp;وسلفونيل</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">پوريا،&nbsp;أو&nbsp;بالتزامن&nbsp;مع&nbsp;الإنسولين.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull; 50&nbsp;ملغم&nbsp;يوميا&nbsp;في&nbsp;الصباح&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;مرض&nbsp;متوسط&nbsp;أو&nbsp;حاد&nbsp;في&nbsp;الكلى&nbsp;أو&nbsp;إذا&nbsp;كنت&nbsp;تخضع&nbsp;للديلزة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الدموية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">كيفية&nbsp;تناول&nbsp;فيلتين</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">قم&nbsp;بتناول&nbsp;الأقراص&nbsp;كاملة&nbsp;مع&nbsp;شرب&nbsp;بعض&nbsp;الماء.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الفترة&nbsp;التي&nbsp;يجب&nbsp;أن&nbsp;تستمر&nbsp;خلالها&nbsp;بتناول&nbsp;فيلتين</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">.&nbsp;تناول&nbsp;فيلتين&nbsp;يوميا&nbsp;طالما&nbsp;يخبرك&nbsp;الطبيب&nbsp;بذلك.&nbsp;قد&nbsp;تحتاج&nbsp;لتناول&nbsp;هذا&nbsp;العلاج&nbsp;لمدة&nbsp;طويلة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull;&nbsp;سيراقب&nbsp;الطبيب&nbsp;حالتك&nbsp;بانتظام&nbsp;للتأكد&nbsp;من&nbsp;أن&nbsp;العلاج&nbsp;يعطي&nbsp;التأثير&nbsp;المطلوب.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;تناولت&nbsp;فيلتين&nbsp;أكثر&nbsp;مما&nbsp;يجب</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;تناولت&nbsp;فيلتين&nbsp;أكثر&nbsp;مما&nbsp;يجب،&nbsp;أو&nbsp;قام&nbsp;شخص&nbsp;آخر&nbsp;بتناول&nbsp;هذا&nbsp;الدواء،&nbsp;قم&nbsp;بالاتصال&nbsp;بالطبيب&nbsp;فورا.&nbsp;قد&nbsp;يكون</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">هناك&nbsp;حاجة&nbsp;لعناية&nbsp;طبية.&nbsp;إذا&nbsp;كنت&nbsp;بحاجة&nbsp;للذهاب&nbsp;إلى&nbsp;الطبيب&nbsp;أو&nbsp;المستشفى،&nbsp;اصطحب&nbsp;معك&nbsp;العبوة.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;نسيت&nbsp;تناول&nbsp;فيلتين</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;نسيت&nbsp;تناول&nbsp;جرعة&nbsp;من&nbsp;هذا&nbsp;الدواء،&nbsp;تناولها&nbsp;في&nbsp;أقرب&nbsp;وقت&nbsp;عند&nbsp;تذكرك.&nbsp;ثم&nbsp;تناول&nbsp;الجرعة&nbsp;التالية&nbsp;في&nbsp;الوقت</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">المعتاد.&nbsp;إذا&nbsp;اقترب&nbsp;موعد&nbsp;الجرعة&nbsp;التالية،&nbsp;لا&nbsp;تتناول&nbsp;الجرعة&nbsp;التي&nbsp;نسيتها.&nbsp;لا&nbsp;تتناول&nbsp;.&nbsp;عة&nbsp;مضاعفة&nbsp;لتعويض</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الجرعة&nbsp;التي&nbsp;نسيتها.</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;توقفت&nbsp;عن&nbsp;تناول&nbsp;فيلتين</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">لاتتوقف&nbsp;عن&nbsp;تناول&nbsp;فيلتين&nbsp;مالم&nbsp;يخبرك&nbsp;الطبيب&nbsp;بذلك.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;كان&nbsp;لديك&nbsp;أية&nbsp;أسئلة&nbsp;عن&nbsp;فترة&nbsp;تناول&nbsp;هذا&nbsp;الدواء،&nbsp;تحدث&nbsp;الى&nbsp;الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">مثل&nbsp;جميع&nbsp;الأدوية،&nbsp;يمكن&nbsp;لهذا&nbsp;الدواء&nbsp;أن&nbsp;يتسبب&nbsp;في&nbsp;آثار&nbsp;جانبية،&nbsp;على&nbsp;الرغم&nbsp;من&nbsp;أنها&nbsp;لا&nbsp;تحصل&nbsp;عند&nbsp;الجميع</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تحتاج&nbsp;بعض&nbsp;الأعراض&nbsp;إلى&nbsp;عناية&nbsp;طبية&nbsp;فورية:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يجب&nbsp;التوقف&nbsp;عن&nbsp;تناول&nbsp;فيلتين&nbsp;و&nbsp;استشر&nbsp;الطبيب&nbsp;فورا&nbsp;إذا&nbsp;عانيت&nbsp;من&nbsp;أي&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;التالية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull;&nbsp;وذمة&nbsp;وعائية&nbsp;(نادرة:&nbsp;قد&nbsp;تؤثر&nbsp;على&nbsp;شخص&nbsp;واحد&nbsp;أو&nbsp;أقل&nbsp;من&nbsp;كل&nbsp;1000&nbsp;شخص):&nbsp;تتضمن&nbsp;الأعراض&nbsp;تورم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الوجه،&nbsp;اللسان&nbsp;أو&nbsp;الحلق،&nbsp;صعوبة&nbsp;في&nbsp;البلع،&nbsp;صعوبة&nbsp;في&nbsp;التنفس،&nbsp;بداية&nbsp;مفاجئة&nbsp;للطفح&nbsp;أو&nbsp;الشرى،&nbsp;التي&nbsp;قد&nbsp;تشير&nbsp;إلى</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">حدوث&nbsp;تفاعل&nbsp;يعرف&nbsp;بالذمة&nbsp;الوعائية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;مرض&nbsp;في&nbsp;الكبد&nbsp;(التهاب&nbsp;الكبد) (نادر):&nbsp;تتضمن&nbsp;الأعراض&nbsp;اصفرار&nbsp;الجلد&nbsp;أو&nbsp;بياض&nbsp;العيون،&nbsp;شعور&nbsp;بالغثيان،</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">فقدان&nbsp;الشهية&nbsp;أو&nbsp;بول&nbsp;داكن&nbsp;اللون،&nbsp;التي&nbsp;قد&nbsp;تشير&nbsp;إلى&nbsp;وجود&nbsp;مرض&nbsp;في&nbsp;الكبد&nbsp;(التهاب&nbsp;الكبد).</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;التهاب&nbsp;في&nbsp;البنكرياس&nbsp;(تكرار&nbsp;حدوثها&nbsp;غير&nbsp;معروف):&nbsp;تتضمن&nbsp;الأعراض&nbsp;ألم&nbsp;حاد&nbsp;و&nbsp;مستمر&nbsp;في&nbsp;البطن&nbsp;(منطقة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">المعدة)،&nbsp;الذي&nbsp;قد&nbsp;ينتشر&nbsp;إلى&nbsp;منطقة&nbsp;الظهر،&nbsp;وكذلك&nbsp;شعور&nbsp;بالغثيان&nbsp;وقيء.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">آثار&nbsp;جانبية&nbsp;أخرى</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عاني&nbsp;بعض&nbsp;المرضى&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;التالية&nbsp;خلال&nbsp;فترة&nbsp;تناول&nbsp;فيلداجلبتين&nbsp;بالتزامن&nbsp;مع&nbsp;ميتفورمین:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">وشائعة&nbsp;(قد&nbsp;تؤثر&nbsp;على&nbsp;شخص&nbsp;واحد&nbsp;أو&nbsp;أقل&nbsp;من&nbsp;كل&nbsp;10&nbsp;أشخاص):&nbsp;رجفان،&nbsp;صداع،&nbsp;شعور&nbsp;بالدوار&nbsp;،&nbsp;الغثيان،</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">انخفاض&nbsp;مستوى&nbsp;الجلوكوز&nbsp;في&nbsp;الدم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;غير&nbsp;شائعة&nbsp;(قد&nbsp;تؤثر&nbsp;على&nbsp;شخص&nbsp;واحد&nbsp;أو&nbsp;أقل&nbsp;من&nbsp;كل&nbsp;100&nbsp;شخص):&nbsp;شعور&nbsp;بالتعب.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عاني&nbsp;بعض&nbsp;المرضى&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;التالية&nbsp;خلال&nbsp;فترة&nbsp;تناول&nbsp;فيلداجلبتين&nbsp;بالتزامن&nbsp;مع&nbsp;سلفونيل&nbsp;يوريا:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull;&nbsp;شائعة:&nbsp;رجفان،&nbsp;صداع،&nbsp;شعور&nbsp;بالدوار&nbsp;،&nbsp;شعور&nbsp;بالضعف،&nbsp;انخفاض&nbsp;مستوى&nbsp;الجلوكوز&nbsp;في&nbsp;الدم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;غير&nbsp;شائعة:&nbsp;إمساك.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;نادرة&nbsp;جدا&nbsp;(قد&nbsp;تؤثر&nbsp;على&nbsp;شخص&nbsp;واحد&nbsp;أو&nbsp;أقل&nbsp;من&nbsp;كل&nbsp;10000&nbsp;شخص):&nbsp;التهاب&nbsp;الحلق،&nbsp;سيلان&nbsp;الأنف</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عاني&nbsp;بعض&nbsp;المرضى&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;التالية&nbsp;خلال&nbsp;فترة&nbsp;تناول&nbsp;فيلداجلتين&nbsp;بالتزامن&nbsp;مع&nbsp;جليتازون</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">وشائعة:&nbsp;زيادة&nbsp;الوزن،&nbsp;تورم&nbsp;اليدين،&nbsp;الكاحلين&nbsp;أو&nbsp;القدمين&nbsp;(وذمة).</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;غير&nbsp;شائعة:&nbsp;صداع،&nbsp;شعور&nbsp;بالضعف،&nbsp;انخفاض&nbsp;مستوى&nbsp;الجلوكوز&nbsp;في&nbsp;الدم.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عاني&nbsp;بعض&nbsp;المرضى&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;التالية&nbsp;خلال&nbsp;فترة&nbsp;تناول&nbsp;فيلداجليتين&nbsp;لوحده</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">شائعة&nbsp;شعر&nbsp;بالدوار&nbsp;.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;غير&nbsp;شائعة&nbsp;صداع،&nbsp;إمساك،&nbsp;تورم&nbsp;الدين،&nbsp;الكاحلين&nbsp;أو&nbsp;القدمين&nbsp;(وذمة)،&nbsp;ألم&nbsp;في&nbsp;المفاصل،&nbsp;انخفاض&nbsp;مستوى</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الجلوكوز&nbsp;في&nbsp;الدم</p><p style="margin-left:0cm; margin-right:0cm">نادرة&nbsp;جدا:&nbsp;التهاب&nbsp;الحلق،&nbsp;سيلان&nbsp;الأنف،&nbsp;حمی</p><p style="margin-left:0cm; margin-right:0cm">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عاني&nbsp;بعض&nbsp;المرضى&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;التالية&nbsp;خلال&nbsp;فترة&nbsp;تناول&nbsp;فيلداجلبتين،&nbsp;ميتفورمین&nbsp;و&nbsp;سلفونيل&nbsp;يوريا&nbsp;مع</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull;&nbsp;شائعة:&nbsp;شعور&nbsp;بالدوار،&nbsp;رجفان،&nbsp;شعور&nbsp;بالضعف،&nbsp;انخفاض&nbsp;مستوى&nbsp;الجلوكوز&nbsp;في&nbsp;الدم،&nbsp;فرط&nbsp;التعرق.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عاني&nbsp;بعض&nbsp;المرضى&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;التالية&nbsp;خلال&nbsp;فترة&nbsp;تناول&nbsp;فيلداجلبتين&nbsp;بالتزامن&nbsp;مع&nbsp;الإنسولين&nbsp;(مع&nbsp;أو</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">بدون&nbsp;الميتفورمین):</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&bull;&nbsp;شائعة:&nbsp;صداع،&nbsp;قشعريرة،&nbsp;شعور&nbsp;بالغثيان،&nbsp;انخفاض&nbsp;مستوى&nbsp;الجلوكوز&nbsp;في&nbsp;الدم،&nbsp;حرقة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;غير&nbsp;شائعة:&nbsp;إسهال،&nbsp;انتفاخ&nbsp;البطن.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تم&nbsp;تسجيل&nbsp;الآثار&nbsp;الجانبية&nbsp;التالية&nbsp;منذ&nbsp;تسويق&nbsp;فيلداجلبتين:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">و&nbsp;آثار&nbsp;جانبية&nbsp;غير&nbsp;معروف&nbsp;تكرار&nbsp;حدوثها&nbsp;(لا&nbsp;يمكن&nbsp;تقدير&nbsp;تكرار&nbsp;حدوثها&nbsp;من&nbsp;المعلومات&nbsp;المتوفرة):&nbsp;طفح</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">مصحوب&nbsp;بالحكة،&nbsp;التهاب&nbsp;البنكرياس،&nbsp;تقشر&nbsp;موضعي&nbsp;في&nbsp;الجلد&nbsp;أو&nbsp;تنفط،&nbsp;ألم&nbsp;في&nbsp;العضلات.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">إذا&nbsp;كان&nbsp;أي&nbsp;من&nbsp;الآثار&nbsp;الجانبية&nbsp;جدية&nbsp;أو&nbsp;إذا&nbsp;لاحظت&nbsp;أي&nbsp;آثار&nbsp;جانبية&nbsp;غير&nbsp;المذكورة&nbsp;في&nbsp;هذه&nbsp;النشرة،&nbsp;يرجي&nbsp;إخبار</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الطبيب&nbsp;أو&nbsp;الصيدلي.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يحفظ&nbsp;بعيدا&nbsp;عن&nbsp;متناول&nbsp;الأطفال&nbsp;و&nbsp;نظر&nbsp;هم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">لا&nbsp;تستخدم&nbsp;أقراص&nbsp;فيلتين&nbsp;بعد&nbsp;تاريخ&nbsp;انتهاء&nbsp;الصلاحية&nbsp;المذكور&nbsp;على&nbsp;الشريط&nbsp;و&nbsp;العلبة&nbsp;الخارجية</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">تاريخ&nbsp;الانتهاء&nbsp;يشير&nbsp;إلى&nbsp;اليوم&nbsp;الأخير&nbsp;من&nbsp;ذلك&nbsp;الشهر&nbsp;.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">فيلتين&nbsp;أقراص:&nbsp;يحفظ&nbsp;بدرجة&nbsp;حرارة&nbsp;دون&nbsp;30&nbsp;في</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">يجب&nbsp;أن&nbsp;لا&nbsp;يتم&nbsp;التخلص&nbsp;من&nbsp;الأدوية&nbsp;عن&nbsp;طريق&nbsp;مياه&nbsp;الصرف&nbsp;الصحي&nbsp;أو&nbsp;النقابات&nbsp;المنزلية&nbsp;اسأل&nbsp;الصيدلي&nbsp;عن</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">كيفية&nbsp;التخلص&nbsp;من&nbsp;الأدوية&nbsp;التي&nbsp;لم&nbsp;تعد&nbsp;مطلوبة.&nbsp;وسوف&nbsp;تساعد&nbsp;هذه&nbsp;التدابير&nbsp;في&nbsp;حماية&nbsp;البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">المادة&nbsp;الفعالة&nbsp;فيلداجلبتين.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">المكونات&nbsp;الأخرى&nbsp;هي&nbsp;لاكتوز&nbsp;لا&nbsp;مائي،&nbsp;ميكروکریستالين&nbsp;سيليلوز،&nbsp;جلايكولات&nbsp;نشا&nbsp;الصوديوم،&nbsp;ستيرات</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">هي المغنيسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">أقراص&nbsp;فيلتين&nbsp;50&nbsp;ملغم</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">أقراص&nbsp;بيضاوية&nbsp;الشكل&nbsp;محدبة&nbsp;الوجهين،&nbsp;ذات&nbsp;لون&nbsp;أبيض&nbsp;إلى&nbsp;أبيض&nbsp;مصفر،&nbsp;محفور&nbsp;على&nbsp;أحد&nbsp;الأوجه&nbsp;PhI</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">معبأة&nbsp;في&nbsp;أشرطة&nbsp;ألومنيوم&nbsp;ألومنيوم،&nbsp;سعد&nbsp;للاستخدام&nbsp;عن&nbsp;طريق&nbsp;الفم.</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">حجم&nbsp;العبوة:</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">7&nbsp;أقراص&nbsp;داخل&nbsp;شريط&nbsp;ألومنيوم/ألومنيوم. 4&nbsp;أشرطة&nbsp;علبة</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">10&nbsp;أقراص&nbsp;داخل&nbsp;شريط&nbsp;ألومنيوم&nbsp;ألومنيوم. 6&nbsp;أشرطة&nbsp;علبة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الشركة&nbsp;الدولية&nbsp;للدواء</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">عمان&nbsp;-&nbsp;الأردن</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">الهاتف:&nbsp;00962-6-5158890 / 5157893</p><p style="margin-left:0cm; margin-right:0cm; text-align:right" dir="RTL">فاکس:00962-6-5154753</p><p>البريد&nbsp;الإلكتروني: marketing@pic-jo.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تنقيح هذه النشرة في 09/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Viltin® 50 mg tablets.
vildagliptin 50 mg tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Viltin® 50 mg tablets: Each tablet contains 50 mg vildagliptin. For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Viltin® tablets.



Viltin® 50 mg Tablets

White to off white oblong normal biconvex tablet engraved with PhI on one face, packed in Alu/Alu blister, intended for oral use.

Pack size: 7 tablets in Alu/Alu blister. 4 blisters/pack. 10 tablets in Alu/Alu blister. 6 blisters/pack.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">As monotherapy</p><p style="margin-left:69.7pt; margin-right:24.25pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">As dual oral therapy in combination with</p><p style="margin-left:105.7pt; margin-right:23.95pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin.</p><p style="margin-left:105.7pt; margin-right:24.1pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance.</p><p style="margin-left:105.7pt; margin-right:24.2pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">As triple oral therapy in combination with</p><p style="margin-left:105.7pt; margin-right:24.3pt; text-align:left; text-indent:-18pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-right:24.2pt; text-align:left">Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">&nbsp; <!--[endif]--><u>Posology</u></p><p style="margin-left:33.65pt; margin-right:0cm; text-align:left"><strong>Adults</strong></p><p style="margin-right:24.15pt; text-align:left">When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in combination with metformin and a sulphonylurea, or in combination with insulin (with or without metformin), the recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one dose of 50 mg in the evening.</p><p style="margin-right:24.05pt; text-align:left">When used in dual combination with a sulphonylurea, the recommended dose of vildagliptin is 50 mg once daily administered in the morning. In this patient population, vildagliptin 100 mg daily was no more effective than vildagliptin 50 mg once daily.</p><p style="margin-right:24.2pt; text-align:left">When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.</p><p style="text-align:left">Doses higher than 100 mg are not recommended.</p><p style="margin-left:33.65pt; margin-right:24.2pt; text-align:left">If a dose of <strong>Viltin<sup>&reg;</sup> </strong>is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.</p><p style="margin-right:24.35pt; text-align:left">The safety and efficacy of vildagliptin as triple oral therapy in combination with metformin and a thiazolidinedione have not been established.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Additional information on special populations</u> Elderly (&ge; 65 years)</p><p style="text-align:left">No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2).</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Renal impairment</p><p style="margin-right:23.7pt; text-align:left">No dose adjustment is required in patients with mild renal impairment (creatinine clearance &ge; 50 ml/min). In patients with moderate or severe renal impairment or with end-stage renal disease (ESRD), the recommended dose of <strong>Viltin<sup>&reg;</sup> </strong>is 50 mg once daily (see also sections 4.4, 5.1 and 5.2).</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Hepatic impairment</p><p style="margin-right:23.6pt; text-align:left"><strong>Viltin<sup>&reg;</sup> </strong>should not be used in patients with hepatic impairment, including patients with pre- treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 3x the upper limit of normal (ULN) (see also sections 4.4 and 5.2).</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Paediatric population</p><p style="margin-right:24.2pt; text-align:left"><strong>Viltin<sup>&reg;</sup> </strong>is not recommended for use in children and adolescents (&lt; 18 years). The safety and efficacy of <strong>Viltin<sup>&reg;</sup> </strong>in children and adolescents (&lt; 18 years) have not been established. No data are available (see also section 5.1).</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Method of administration</u></p><p style="text-align:left">Oral use</p><p style="text-align:left"><strong>Viltin<sup>&reg;</sup> </strong>can be administered with or without a meal (see also section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.65pt; margin-right:0cm; text-align:left"><strong><u>General</u></strong></p><p style="text-align:left"><strong>Viltin<sup>&reg;</sup> </strong>is not a substitute for insulin in insulin-requiring patients. <strong>Viltin<sup>&reg;</sup> </strong>should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Renal impairment</u></p><p style="margin-right:24.05pt; text-align:left">There is limited experience in patients with ESRD on haemodialysis. Therefore <strong>Viltin<sup>&reg;</sup> </strong>should be used with caution in these patients (see also sections 4.2, 5.1 and 5.2).</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Hepatic impairment</u></p><p style="margin-right:44.05pt; text-align:left"><strong>Viltin<sup>&reg;</sup> </strong>should not be used in patients with hepatic impairment, including patients with pre- treatment ALT or AST &gt; 3x ULN (see also sections 4.2 and 5.2).</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Liver enzyme monitoring</u></p><p style="margin-left:33.65pt; margin-right:23.7pt; text-align:left">Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function test results returned to normal after discontinuation of treatment. Liver function tests should be performed prior to the initiation of treatment with <strong>Viltin<sup>&reg;</sup> </strong>in order to know the patient&#39;s baseline value. Liver function should be monitored during treatment with <strong>Viltin<sup>&reg;</sup> </strong>at three-month intervals during the first year and periodically thereafter. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return(s) to normal. Should an increase in AST or ALT of 3x ULN or greater persist, withdrawal of <strong>Viltin<sup>&reg;</sup> </strong>therapy is recommended.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:24.25pt; text-align:left">Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue <strong>Viltin<sup>&reg;</sup></strong>.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Following withdrawal of treatment with <strong>Viltin<sup>&reg;</sup> </strong>and LFT normalisation, treatment with <strong>Viltin<sup>&reg;</sup></strong></p><p style="text-align:left">should not be reinitiated.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Cardiac failure</u></p><p style="margin-left:33.65pt; margin-right:23.6pt; text-align:left">A clinical trial of vildagliptin in patients with New York Heart Association (NYHA) functional class I-III showed that treatment with vildagliptin was not associated with a change in left- ventricular function or worsening of pre-existing congestive heart failure (CHF) versus placebo. Clinical experience in patients with NYHA functional class III treated with vildagliptin is still limited and results are inconclusive (see section 5.1).</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-right:24.2pt; text-align:left">There is no experience of vildagliptin use in clinical trials in patients with NYHA functional class IV and therefore use is not recommended in these patients.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Skin disorders</u></p><p style="margin-right:24.1pt; text-align:left">Skin lesions, including blistering and ulceration have been reported in extremities of monkeys in non-clinical toxicology studies (see section 5.3). Although skin lesions were not observed at</p><p style="text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:24.25pt; text-align:left">an increased incidence in clinical trials, there was limited experience in patients with diabetic skin complications.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:24.35pt; text-align:left">Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Acute pancreatitis</u></p><p style="margin-right:24.3pt; text-align:left">Use of vildagliptin has been associated with a risk of developing acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:23.8pt; text-align:left">If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Hypoglycaemia</u></p><p style="margin-right:24.2pt; text-align:left">Sulphonylureas are known to cause hypoglycaemia. Patients receiving vildagliptin in combination with a sulphonylurea may be at risk for hypoglycaemia. Therefore, a lower dose of sulphonylurea may be considered to reduce the risk of hypoglycaemia.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Excipients</u></p><p style="margin-right:23.95pt; text-align:left">The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:23.85pt; text-align:left">Vildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Combination with pioglitazone, metformin and glyburide</u></p><p style="text-align:left">Results from studies conducted with these oral antidiabetics have shown no clinically relevant pharmacokinetic interactions.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Digoxin (Pgp substrate), warfarin (CYP2C9 substrate)</u></p><p style="margin-left:33.65pt; margin-right:24.05pt; text-align:left">Clinical&nbsp;&nbsp; studies&nbsp;&nbsp; performed&nbsp;&nbsp; with&nbsp;&nbsp; healthy&nbsp;&nbsp; subjects&nbsp;&nbsp; have&nbsp;&nbsp; shown&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; no&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clinically&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; relevant pharmacokinetic interactions. However, this has not been established in the target population.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Combination with amlodipine, ramipril, valsartan or simvastatin</u></p><p style="text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:24.1pt; text-align:left">Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were observed after co-administration with vildagliptin.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left"><u>Pregnancy</u></p><p style="margin-right:23.9pt; text-align:left">There are no adequate data from the use of vildagliptin in pregnant women. Studies in animals have shown reproductive toxicity at high doses (see section 5.3). The potential risk for humans is unknown. Due to lack of human data, <strong>Viltin<sup>&reg;</sup> </strong>should not be used during pregnancy.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p style="text-align:left"><u>Breast-feeding</u></p><p style="margin-right:44.05pt; text-align:left">It is unknown whether vildagliptin is excreted in human milk. Animal studies have shown excretion of vildagliptin in milk. <strong>Viltin<sup>&reg;</sup> </strong>should not be used during breast-feeding.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Fertility</u></p><p style="text-align:left">No studies on the effect on human fertility have been conducted for <strong>Viltin<sup>&reg;</sup> </strong>(see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No studies on the effects on the ability to drive and use machines have been performed. Patients who experience dizziness as an adverse reaction should avoid driving vehicles or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left"><u>Summary of the safety profile</u></p><p style="margin-right:23.8pt; text-align:left">Safety data were obtained from a total of 3,784 patients exposed to vildagliptin at a daily dose of 50 mg (once daily) or 100 mg (50 mg twice daily or 100 mg once daily) in controlled trials of at least 12 weeks duration. Of these patients, 2,264 patients received vildagliptin as monotherapy and 1,520 patients received vildagliptin in combination with another medicinal product. 2,682 patients were treated with vildagliptin 100 mg daily (either 50 mg twice daily or 100 mg once daily) and 1,102 patients were treated with vildagliptin 50 mg once daily.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:24pt; text-align:left">The majority of adverse reactions in these trials were mild and transient, not requiring treatment discontinuations. No association was found between adverse reactions and age, ethnicity, duration of exposure or daily dose.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:23.7pt; text-align:left">Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment. In data from controlled monotherapy and add-on therapy trials of up to 24 weeks in duration, the incidence of ALT or AST elevations &ge; 3x ULN (classified as present on at least 2 consecutive measurements or at the final on-treatment visit) was 0.2%, 0.3% and 0.2% for vildagliptin 50 mg once daily, vildagliptin 50 mg twice daily</p><p style="text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:24.25pt; text-align:left">and all comparators, respectively. These elevations in transaminases were generally asymptomatic, non-progressive in nature and not associated with cholestasis or jaundice.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-right:23.9pt; text-align:left">Rare cases of angioedema have been reported on vildagliptin at a similar rate to controls. A greater proportion of cases were reported when vildagliptin was administered in combination with an angiotensin converting enzyme inhibitor (ACE-Inhibitor). The majority of events were mild in severity and resolved with ongoing vildagliptin treatment.</p><p style="text-align:left"><u>Tabulated list of adverse reactions</u></p><p style="margin-right:23.7pt; text-align:left">Adverse reactions reported in patients who received Vildagliptin in double-blind studies as monotherapy and add-on therapies are listed below for each indication by system organ class and absolute frequency. Frequencies are defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Combination with metformin</p><p style="margin-left:0cm; text-align:left"><strong><em>&nbsp;</em></strong></p><p style="margin-left:33.65pt; margin-right:23.55pt; text-align:left"><strong>Table 1 Adverse reactions reported in patients who received vildagliptin 100 mg daily&nbsp; in combination with metformin in double-blind studies (N=208)</strong></p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:499.6pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; text-align:left">Hypoglycaemia</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:499.6pt" colspan="2"><p style="text-align:left"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.1pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:17.1pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; margin-right:0cm; text-align:left">Tremor</p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:16.75pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; text-align:left">Headache</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; margin-right:0cm; text-align:left">Dizziness</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Uncommon</p></td><td style="height:17.25pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; text-align:left">Fatigue</p></td></tr><tr><td style="border-color:black; height:17.1pt; vertical-align:top; width:499.6pt" colspan="2"><p style="text-align:left"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; text-align:left">Nausea</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:33.65pt; margin-right:0cm; text-align:left"><strong><em><u>Description of selected adverse reactions</u></em></strong></p><p style="margin-right:24pt; text-align:left">In controlled clinical trials with the combination of vildagliptin 100 mg daily + metformin, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily + metformin or the placebo + metformin treatment groups.</p><p style="text-align:left">In clinical trials, the incidence of hypoglycaemia was common in patients receiving vildagliptin</p><p style="margin-right:23.85pt; text-align:left">100 mg daily in combination with metformin (1%) and uncommon in patients receiving placebo + metformin (0.4%). No severe hypoglycaemic events were reported in the vildagliptin arms.</p><p style="margin-right:24.5pt; text-align:left">In clinical trials, weight did not change from baseline when vildagliptin 100 mg daily was added to metformin (+0.2 kg and -1.0 kg for vildagliptin and placebo, respectively).</p><p style="margin-right:24.3pt; text-align:left">Clinical trials of up to more than 2 years&#39; duration did not show any additional safety signals or unforeseen risks when vildagliptin was added on to metformin.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Combination with a sulphonylurea</p><p style="text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong><em>&nbsp;</em></strong></p><p style="margin-left:33.65pt; margin-right:23.7pt; text-align:left"><strong>Table 2 Adverse reactions reported in patients who received vildagliptin 50 mg in combination with a sulphonylurea in double-blind studies (N=170)</strong></p><p style="margin-left:0cm; text-align:left"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:503.4pt" colspan="2"><p style="text-align:left"><strong>Infections and infestations</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:251.7pt"><p style="text-align:left">Very rare</p></td><td style="height:17.25pt; vertical-align:top; width:251.7pt"><p style="margin-left:1.4pt; text-align:left">Nasopharyngitis</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:503.4pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:251.7pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:251.7pt"><p style="margin-left:1.4pt; text-align:left">Hypoglycaemia</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:503.4pt" colspan="2"><p style="text-align:left"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:251.7pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:251.7pt"><p style="margin-left:1.4pt; text-align:left">Tremor</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:251.7pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:251.7pt"><p style="margin-left:1.4pt; text-align:left">Headache</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:251.7pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:251.7pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Dizziness</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:251.7pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:251.7pt"><p style="margin-left:1.4pt; text-align:left">Asthenia</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:503.4pt" colspan="2"><p style="text-align:left"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:251.7pt"><p style="text-align:left">Uncommon</p></td><td style="height:17.25pt; vertical-align:top; width:251.7pt"><p style="margin-left:1.4pt; text-align:left">Constipation</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:33.65pt; margin-right:0cm; text-align:left"><strong><em><u>Description of selected adverse reactions</u></em></strong></p><p style="margin-right:23.95pt; text-align:left">In controlled clinical trials with the combination of vildagliptin 50 mg + a sulphonylurea, the overall incidence of withdrawals due to adverse reactions was 0.6% in the vildagliptin 50 mg + sulphonylurea vs 0% in the placebo + sulphonylurea treatment group.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:24.2pt; text-align:left">In clinical trials, the incidence of hypoglycaemia when vildagliptin 50 mg once daily was added to glimepiride was 1.2% versus 0.6% for placebo + glimepiride. No severe hypoglycaemic events were reported in the vildagliptin arms.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:23.9pt; text-align:left">In clinical trials, weight did not change from baseline when vildagliptin 50 mg daily was added to glimepiride (-0.1 kg and -0.4 kg for vildagliptin and placebo, respectively).</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Combination with a thiazolidinedione</p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong><em>&nbsp;</em></strong></p><p style="margin-left:33.65pt; margin-right:23.65pt; text-align:left"><strong>Table 3 Adverse reactions reported in patients who received Vildagliptin 100 mg daily in combination with a thiazolidinedione in double-blind studies (N=158)</strong></p><p style="margin-left:0cm; text-align:left"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:20.95pt; vertical-align:top; width:508.7pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:black; height:23.5pt; vertical-align:top; width:254.35pt"><p style="text-align:left">Common</p></td><td style="height:23.5pt; vertical-align:top; width:254.35pt"><p style="margin-left:1.4pt; text-align:left">Weight increase</p></td></tr><tr><td style="border-color:black; height:24.55pt; vertical-align:top; width:254.35pt"><p style="text-align:left">Uncommon</p></td><td style="height:24.55pt; vertical-align:top; width:254.35pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Hypoglycaemia</p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:508.7pt" colspan="2"><p style="text-align:left"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:254.35pt"><p style="text-align:left">Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:254.35pt"><p style="margin-left:1.4pt; text-align:left">Headache</p></td></tr><tr><td style="border-color:black; height:16.85pt; vertical-align:top; width:254.35pt"><p style="text-align:left">Uncommon</p></td><td style="height:16.85pt; vertical-align:top; width:254.35pt"><p style="margin-left:1.4pt; text-align:left">Asthenia</p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:508.7pt" colspan="2"><p style="text-align:left"><strong>Vascular disorders</strong></p></td></tr></tbody></table><p style="text-align:left">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:254.35pt"><p style="text-align:left">Common</p></td><td style="border-color:black; height:16.75pt; vertical-align:top; width:254.35pt"><p style="margin-left:1.4pt; text-align:left">Oedema peripheral</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:33.65pt; margin-right:0cm; text-align:left"><strong><em><u>Description of selected adverse reactions</u></em></strong></p><p style="margin-right:23.85pt; text-align:left">In controlled clinical trials with the combination of vildagliptin 100 mg daily+ a thiazolidinedione, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily + thiazolidinedione or the placebo + thiazolidinedione treatment groups.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:24.25pt; text-align:left">In clinical trials, the incidence of hypoglycaemia was uncommon in patients receiving vildagliptin + pioglitazone (0.6%) but common in patients receiving placebo + pioglitazone (1.9%). No severe hypoglycaemic events were reported in the vildagliptin arms.</p><p style="margin-right:23.7pt; text-align:left">In the pioglitazone add-on study, the absolute weight increases with placebo, Vildagliptin 100 mg daily were 1.4 and 2.7 kg, respectively.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-right:23.8pt; text-align:left">The incidence of peripheral oedema when vildagliptin 100 mg daily was added to a maximum dose of background pioglitazone (45 mg once daily) was 7.0%, compared to 2.5% for background pioglitazone alone.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Monotherapy</p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong><em>&nbsp;</em></strong></p><p style="margin-left:33.65pt; margin-right:24.05pt; text-align:left"><strong>Table 4 Adverse reactions reported in patients who received Vildagliptin 100 mg daily as monotherapy in double-blind studies (N=1,855)</strong></p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:518.4pt" colspan="2"><p style="text-align:left"><strong>Infections and infestations</strong></p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:259.25pt"><p style="text-align:left">Very rare</p></td><td style="height:16.75pt; vertical-align:top; width:259.15pt"><p style="margin-left:1.4pt; text-align:left">Upper respiratory tract infection</p></td></tr><tr><td style="border-color:black; height:16.9pt; vertical-align:top; width:259.25pt"><p style="text-align:left">Very rare</p></td><td style="height:16.9pt; vertical-align:top; width:259.15pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Nasopharyngitis</p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:518.4pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:259.25pt"><p style="text-align:left">Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:259.15pt"><p style="margin-left:1.4pt; text-align:left">Hypoglycaemia</p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:518.4pt" colspan="2"><p style="text-align:left"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:black; height:16.85pt; vertical-align:top; width:259.25pt"><p style="text-align:left">Common</p></td><td style="height:16.85pt; vertical-align:top; width:259.15pt"><p style="margin-left:1.4pt; text-align:left">Dizziness</p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:259.25pt"><p style="text-align:left">Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:259.15pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Headache</p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:518.4pt" colspan="2"><p style="text-align:left"><strong>Vascular disorders</strong></p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:259.25pt"><p style="text-align:left">Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:259.15pt"><p style="margin-left:1.4pt; text-align:left">Oedema peripheral</p></td></tr><tr><td style="border-color:black; height:16.85pt; vertical-align:top; width:518.4pt" colspan="2"><p style="text-align:left"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:259.25pt"><p style="text-align:left">Uncommon</p></td><td style="height:16.75pt; vertical-align:top; width:259.15pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Constipation</p></td></tr><tr><td style="border-color:black; height:16.8pt; vertical-align:top; width:518.4pt" colspan="2"><p style="text-align:left"><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="border-color:black; height:16.85pt; vertical-align:top; width:259.25pt"><p style="text-align:left">Uncommon</p></td><td style="height:16.85pt; vertical-align:top; width:259.15pt"><p style="margin-left:1.4pt; text-align:left">Arthralgia</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:33.65pt; text-align:left"><strong><em><u>Description of selected adverse reactions</u></em></strong></p><p style="margin-right:24.25pt; text-align:left">In addition, in controlled monotherapy trials with vildagliptin the overall incidence of withdrawals due to adverse reactions was no greater for patients treated with vildagliptin at doses of 100 mg daily (0.3%) than for placebo (0.6%) or comparators (0.5%).</p><p style="text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:23.85pt; text-align:left">In comparative controlled monotherapy studies, hypoglycaemia was uncommon, reported in 0.4% (7 of 1,855) of patients treated with vildagliptin 100 mg daily compared to 0.2% (2 of 1,082) of patients in the groups treated with an active comparator or placebo, with no serious or severe events reported.</p><p style="margin-left:33.65pt; margin-right:24.5pt; text-align:left">In clinical trials, weight did not change from baseline when vildagliptin 100 mg daily was administered as monotherapy (-0.3 kg and -1.3 kg for vildagliptin and placebo, respectively).</p><p style="margin-right:24.15pt; text-align:left">Clinical trials of up to 2 years&#39; duration did not show any additional safety signals or unforeseen risks with vildagliptin monotherapy.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Combination with metformin and a sulphonylurea</p><p style="margin-left:33.65pt; margin-right:23.75pt; text-align:left"><strong>Table 5 Adverse reactions reported in patients who received Vildagliptin 50 mg twice daily in combination with metformin and a sulphonylurea (N=157)</strong></p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:17.75pt; vertical-align:top; width:499.6pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutritional disorders</strong></p></td></tr><tr><td style="border-color:black; height:16.85pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:16.85pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; text-align:left">Hypoglycaemia</p></td></tr><tr><td style="border-color:black; height:17.7pt; vertical-align:top; width:499.6pt" colspan="2"><p style="text-align:left"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.0pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:17.0pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; text-align:left">Dizziness, tremor</p></td></tr><tr><td style="border-color:black; height:16.85pt; vertical-align:top; width:499.6pt" colspan="2"><p style="text-align:left"><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.7pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:17.7pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; text-align:left">Hyperhidrosis</p></td></tr><tr><td style="border-color:black; height:16.85pt; vertical-align:top; width:499.6pt" colspan="2"><p style="text-align:left"><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="border-color:black; height:17.7pt; vertical-align:top; width:249.75pt"><p style="text-align:left">Common</p></td><td style="height:17.7pt; vertical-align:top; width:249.85pt"><p style="margin-left:1.55pt; text-align:left">Asthenia</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:33.65pt; text-align:left"><strong><em><u>Description of selected adverse reactions</u></em></strong></p><p style="margin-right:23.95pt; text-align:left">There were no withdrawals due to adverse reactions reported in the vildagliptin + metformin + glimepiride treatment group versus 0.6% in the placebo + metformin + glimepiride treatment group.</p><p style="margin-right:24.2pt; text-align:left">The incidence of hypoglycaemia was common in both treatment groups (5.1% for the vildagliptin + metformin + glimepiride group versus 1.9% for the placebo + metformin + glimepiride group). One severe hypoglycaemic event was reported in the vildagliptin group.</p><p style="margin-right:24.3pt; text-align:left">At the end of the study, effect on mean body weight was neutral (+0.6 kg in the vildagliptin group and -0.1 kg in the placebo group).</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Combination with insulin</p><p style="margin-left:33.65pt; margin-right:23.65pt; text-align:left"><strong>Table 6 Adverse reactions reported in patients who received Vildagliptin 100 mg daily in combination with insulin (with or without metformin) in double-blind studies (N=371)</strong></p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:506.4pt" colspan="2"><p style="text-align:left"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:253.25pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:253.15pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Decreased blood glucose</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:506.4pt" colspan="2"><p style="text-align:left"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:253.25pt"><p style="text-align:left">Common</p></td><td style="height:17.25pt; vertical-align:top; width:253.15pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Headache, chills</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:506.4pt" colspan="2"><p style="text-align:left"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.2pt; vertical-align:top; width:253.25pt"><p style="text-align:left">Common</p></td><td style="height:17.2pt; vertical-align:top; width:253.15pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Nausea, gastro-oesophageal reflux disease</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:253.25pt"><p style="text-align:left">Uncommon</p></td><td style="height:17.25pt; vertical-align:top; width:253.15pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Diarrhoea, flatulence</p></td></tr></tbody></table><p style="text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:33.65pt; margin-right:0cm; text-align:left"><strong><em><u>Description of selected adverse reactions</u></em></strong></p><p style="margin-right:24.25pt; text-align:left">In controlled clinical trials using vildagliptin 50 mg twice daily in combination with insulin, with or without concomitant metformin, the overall incidence of withdrawals due to adverse reactions was 0.3% in the vildagliptin treatment group and there were no withdrawals in the placebo group.</p><p style="margin-right:23.8pt; text-align:left">The incidence of hypoglycaemia was similar in both treatment groups (14.0% in the vildagliptin group vs 16.4% in the placebo group). Two patients reported severe hypoglycaemic events in the vildagliptin group, and 6 patients in the placebo group.</p><p style="margin-right:23.8pt; text-align:left">At the end of the study, effect on mean body weight was neutral (+0.6 kg change from baseline in the vildagliptin group and no weight change in the placebo group).</p><p style="text-align:left"><u>Post-marketing experience</u></p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:33.65pt; margin-right:0cm; text-align:left"><strong>Table 7 Post-marketing adverse reactions</strong></p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:16.75pt; vertical-align:top; width:505.7pt" colspan="2"><p style="text-align:left"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:252.9pt"><p style="text-align:left">Not known</p></td><td style="height:17.25pt; vertical-align:top; width:252.8pt"><p style="margin-left:1.4pt; text-align:left">Pancreatitis</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:505.7pt" colspan="2"><p style="text-align:left"><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="border-color:black; height:58.5pt; vertical-align:top; width:252.9pt"><p style="text-align:left">Not known</p></td><td style="height:58.5pt; vertical-align:top; width:252.8pt"><p style="margin-left:1.4pt; margin-right:16.85pt; text-align:left">Hepatitis (reversible upon discontinuation of the medicinal product)</p><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Abnormal liver function tests (reversible upon discontinuation of the medicinal product)</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:505.7pt" colspan="2"><p style="text-align:left"><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:252.9pt"><p style="text-align:left">Not known</p></td><td style="height:17.25pt; vertical-align:top; width:252.8pt"><p style="margin-left:1.4pt; text-align:left">Myalgia</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:505.7pt" colspan="2"><p style="text-align:left"><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="border-color:black; height:30.8pt; vertical-align:top; width:252.9pt"><p style="text-align:left">Not known</p></td><td style="height:30.8pt; vertical-align:top; width:252.8pt"><p style="margin-left:1.4pt; text-align:left">Urticaria</p><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">Bullous or exfoliative skin lesions</p></td></tr></tbody></table><p style="margin-left:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:33.65pt; text-align:left"><strong>To report any side effect(s):</strong></p><p style="margin-left:33.65pt; margin-right:0cm; text-align:left"><strong>&bull;Saudi Arabia:</strong></p><p style="margin-left:33.65pt; margin-right:208.7pt; text-align:left">The National Pharmacovigilance and Drug Safety Center (NPC): Fax: +966-11-205-7662</p><p style="margin-left:33.65pt; text-align:left">Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:33.65pt; margin-right:0cm; text-align:left">Reporting hotline: 19999</p><p style="margin-left:33.65pt; margin-right:372.55pt; text-align:left">E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p><p style="margin-left:33.65pt; text-align:left"><strong>&bull;United Arab of Emirates:</strong></p><p style="margin-left:33.65pt; margin-right:290.6pt; text-align:left">Pharmacovigilance and Medical Device Section P.O. Box: 1853 , Tel: 80011111</p><p style="margin-left:33.65pt; text-align:left">Email : pv@moh.gov.ae</p><p style="margin-left:33.65pt; margin-right:281.85pt; text-align:left">Drug Department, Ministry of Health &amp; Prevention Dubai-UAE.</p><p style="margin-left:33.65pt; text-align:left"><strong>&bull;Other GCC States:</strong></p><p style="text-align:left"><br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Information regarding overdose with vildagliptin is limited.</p><p style="text-align:left"><u>Symptoms</u></p><p style="margin-right:23.85pt; text-align:left">Information on the likely symptoms of overdose was taken from a rising dose tolerability study in healthy subjects given Vildagliptin for 10 days. At 400 mg, there were three cases of muscle pain, and individual cases of mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels. At 600 mg, one subject experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), aspartate aminotransferase (AST), C-reactive protein (CRP) and myoglobin levels. Three other subjects experienced oedema of the feet, with paraesthesia in two cases. All symptoms and laboratory abnormalities resolved without treatment after discontinuation of the study medicinal product.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Management</u></p><p style="margin-right:24pt; text-align:left">In the event of an overdose, supportive management is recommended. Vildagliptin cannot be removed by haemodialysis. However, the major hydrolysis metabolite (LAY 151) can be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:44.05pt; text-align:left">Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code: A10BH02</p><p style="text-align:left">Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Mechanism of action</u></p><p style="margin-right:23.85pt; text-align:left">The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Pharmacodynamic effects</u></p><p style="margin-right:23.6pt; text-align:left">By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA-&beta; (Homeostasis Model Assessment&ndash; &beta;), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently- sampled meal tolerance test. In non-diabetic (normal glycaemic) individuals, vildagliptin does not stimulate insulin secretion or reduce glucose levels.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-right:24.05pt; text-align:left">By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:24.25pt; text-align:left">The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:24.2pt; text-align:left">The known effect of increased GLP-1 levels delaying gastric emptying is not observed with vildagliptin treatment.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Clinical efficacy and safety</u></p><p style="margin-right:23.75pt; text-align:left">More than 15,000 patients with type 2 diabetes participated in double-blind placebo- or active- controlled clinical trials of up to more than 2 years&#39; treatment duration. In these studies, vildagliptin was administered to more than 9,000 patients at daily doses of 50 mg once daily, 50 mg twice daily or 100 mg once daily. More than 5,000 male and more than 4,000 female patients received vildagliptin 50 mg once daily or 100 mg daily. More than 1,900 patients receiving vildagliptin 50 mg once daily or 100 mg daily were &ge; 65 years. In these trials, vildagliptin was administered as monotherapy in drug-na&iuml;ve patients with type 2 diabetes or in combination in patients not adequately controlled by other antidiabetic medicinal products.</p><p style="margin-left:33.65pt; margin-right:23.65pt; text-align:left">Overall, vildagliptin improved glycaemic control when given as monotherapy or when used in combination with metformin, a sulphonylurea, and a thiazolidinedione, as measured by clinically relevant reductions in HbA<sub>1c</sub> from baseline at study endpoint (see Table 8).</p><p style="margin-right:24pt; text-align:left">In clinical trials, the magnitude of HbA<sub>1c</sub> reductions with vildagliptin was greater in patients with higher baseline HbA<sub>1c</sub>.</p><p style="margin-right:23.7pt; text-align:left">In a 52-week double-blind controlled trial, vildagliptin (50 mg twice daily) reduced baseline HbA<sub>1c</sub> by -1% compared to -1.6% for metformin (titrated to 2 g/day) statistical non-inferiority was not achieved. Patients treated with vildagliptin reported significantly lower incidences of gastrointestinal adverse reactions versus those treated with metformin.</p><p style="margin-right:23.7pt; text-align:left">In a 24-week double-blind controlled trial, vildagliptin (50 mg twice daily) was compared to rosiglitazone (8 mg once daily). Mean reductions were -1.20% with vildagliptin and -1.48% with rosiglitazone in patients with mean baseline HbA<sub>1c</sub> of 8.7%. Patients receiving rosiglitazone experienced a mean increase in weight (+1.6 kg) while those receiving vildagliptin experienced no weight gain (-0.3 kg). The incidence of peripheral oedema was lower in the vildagliptin group than in the rosiglitazone group (2.1% vs. 4.1% respectively).</p><p style="margin-right:23.5pt; text-align:left">In a clinical trial of 2 years&#39; duration, vildagliptin (50 mg twice daily) was compared to gliclazide (up to 320 mg/day). After two years, mean reduction in HbA<sub>1c</sub> was -0.5% for vildagliptin and -0.6% for gliclazide, from a mean baseline HBA<sub>1c</sub> of 8.6%. Statistical non- inferiority was not achieved. Vildagliptin was associated with fewer hypoglycaemic events (0.7%) than gliclazide (1.7%).</p><p style="margin-left:33.65pt; margin-right:23.75pt; text-align:left">In a 24-week trial, vildagliptin (50 mg twice daily) was compared to pioglitazone (30 mg once daily) in patients inadequately controlled with metformin (mean daily dose: 2020 mg). Mean reductions from baseline HbA<sub>1c</sub> of 8.4% were -0.9% with vildagliptin added to metformin and - 1.0% with pioglitazone added to metformin. A mean weight gain of +1.9 kg was observed in patients receiving pioglitazone added to metformin compared to +0.3 kg in those receiving vildagliptin added to metformin.</p><p style="margin-right:23.7pt; text-align:left">In a clinical trial of 2 years&#39; duration, vildagliptin (50 mg twice daily) was compared to glimepiride (up to 6 mg/day &ndash; mean dose at 2 years: 4.6 mg) in patients treated with metformin (mean daily dose: 1894 mg). After 1 year mean reductions in HbA<sub>1c</sub> were -0.4% with vildagliptin added to metformin and -0.5% with glimepiride added to metformin, from a mean baseline HbA<sub>1c</sub> of 7.3%. Body weight change with vildagliptin was -0.2 kg vs +1.6 kg with glimepiride. The incidence of hypoglycaemia was significantly lower in the vildagliptin group (1.7%) than in the glimepiride group (16.2%). At study endpoint (2 years), the</p><p style="text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:24.35pt; text-align:left">HbA<sub>1c</sub> was similar to baseline values in both treatment groups and the body weight changes and hypoglycaemia differences were maintained.</p><p style="margin-left:33.65pt; margin-right:23.75pt; text-align:left">In a 52-week trial, vildagliptin (50 mg twice daily) was compared to gliclazide (mean daily dose: 229.5 mg) in patients inadequately controlled with metformin (metformin dose at baseline 1928 mg/day). After 1 year, mean reductions in HbA<sub>1c</sub>were -0.81% with vildagliptin added to metformin (mean baseline HbA<sub>1c</sub> 8.4%) and -0.85% with gliclazide added to metformin (mean baseline HbA<sub>1c</sub> 8.5%); statistical non-inferiority was achieved (95% CI -0.11</p><p style="margin-right:24.3pt; text-align:left">&ndash; 0.20). Body weight change with vildagliptin was +0.1 kg compared to a weight gain of +1.4 kg with gliclazide.</p><p style="margin-right:23.7pt; text-align:left">In a 24-week trial the efficacy of the fixed dose combination of vildagliptin and metformin (gradually titrated to a dose of 50 mg/500 mg twice daily or 50 mg/1000 mg twice daily) as initial therapy in drug-na&iuml;ve patients was evaluated. Vildagliptin/metformin 50 mg/1000 mg twice daily reduced HbA<sub>1c</sub> by -1.82%, vildagliptin/metformin 50 mg/500 mg twice daily by - 1.61%, metformin 1000 mg twice daily by -1.36% and vildagliptin 50 mg twice daily by -1.09% from a mean baseline HbA<sub>1c</sub> of 8.6%. The decrease in HbA<sub>1c</sub> observed in patients with a baseline &ge;10.0% was greater.</p><p style="margin-left:33.65pt; margin-right:23.9pt; text-align:left">A 24-week, multi-centre, randomised, double-blind, placebo-controlled trial was conducted to evaluate the treatment effect of vildagliptin 50 mg once daily compared to placebo in 515 patients with type 2 diabetes and moderate renal impairment (N=294) or severe renal impairment (N=221). 68.8% and 80.5% of the patients with moderate and severe renal impairment respectively were treated with insulin (mean daily dose of 56 units and 51.6 units respectively) at baseline. In patients with moderate renal impairment vildagliptin significantly decreased HbA<sub>1c</sub> compared with placebo (difference of -0.53%) from a mean baseline of 7.9%.&nbsp; In&nbsp; patients&nbsp; with&nbsp; severe&nbsp; renal&nbsp; impairment,&nbsp; vildagliptin&nbsp; significantly &nbsp;decreased&nbsp; HbA<sub>1c</sub> compared with placebo (difference of -0.56%) from a mean baseline of 7.7%.</p><p style="margin-right:23.6pt; text-align:left">A 24-week randomised, double-blind, placebo-controlled trial was conducted in 318 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with metformin (&ge;1500 mg daily) and glimepiride (&ge;4 mg daily). Vildagliptin in combination with metformin and glimepiride significantly decreased HbA<sub>1c</sub> compared with placebo.The placebo- adjusted mean reduction from a mean baseline HbA<sub>1c</sub> of 8.8% was -0.76%.</p><p style="margin-right:23.75pt; text-align:left">A 24-week randomised, double-blind, placebo-controlled trial was conducted in 449 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with a stable dose of basal or premixed insulin (mean daily dose 41 units), with concomitant use of metformin (N=276) or without concomitant metformin (N=173). Vildagliptin in combination with insulin significantly decreased HbA<sub>1c</sub> compared with placebo. In the overall population, the placebo-adjusted mean reduction from a mean baseline HbA<sub>1c</sub> 8.8% was -0.72%. In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA<sub>1c</sub> was -0.63% and -0.84%, respectively. The incidence of hypoglycaemia in the overall population was 8.4% and 7.2% in the vildagliptin and placebo groups, respectively. Patients receiving vildagliptin experienced no weight gain (+0.2 kg) while those receiving placebo experienced weight reduction (-0.7 kg).</p><p style="margin-left:33.65pt; margin-right:23.55pt; text-align:left">In another 24-week study in patients with more advanced type 2 diabetes not adequately controlled on insulin (short and longer acting, average insulin dose 80 IU/day), the mean reduction in HbA<sub>1c</sub> when vildagliptin (50 mg twice daily) was added to insulin was statistically significantly greater than with placebo plus insulin (0.5% vs. 0.2%). The incidence of</p><p style="text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:24.4pt; text-align:left">hypoglycaemia was lower in the vildagliptin group than in the placebo group (22.9% vs. 29.6%).</p><p style="margin-left:33.65pt; margin-right:23.65pt; text-align:left">A 52-week multi-centre, randomised, double-blind trial was conducted in patients with type 2 diabetes and congestive heart failure (NYHA functional class I-III) to evaluate the effect of vildagliptin 50 mg twice daily (N=128) compared to placebo (N=126) on left-ventricular ejection fraction (LVEF). Vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing CHF. Adjudicated cardiovascular events were balanced overall. There were more cardiac events in vildagliptin treated patients with NYHA class III heart failure compared to placebo. However, there were imbalances in baseline cardiovascular risk favouring placebo and the number of events was low, precluding firm conclusions. Vildagliptin significantly decreased HbA1c compared with placebo (difference of 0.6%) from a mean baseline of 7.8% at week 16. In the subgroup with NYHA class III, the decrease in HbA1c compared to placebo was lower (difference 0.3%) but this conclusion is limited by the small number of patients (n=44). The incidence of hypoglycaemia in the overall population was 4.7% and 5.6% in the vildagliptin and placebo groups, respectively.</p><p style="text-align:left">Cardiovascular risk</p><p style="margin-right:23.8pt; text-align:left">A meta-analysis of independently and prospectively adjudicated cardiovascular events from 25 phase III clinical studies of up to more than 2 years duration was performed and showed that vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators. The composite endpoint of adjudicated cardiovascular and cerebrovascular (CCV) events [acute coronary syndrome (ACS), transient ischaemic attack (with imaging evidence of infarction), stroke or CCV death], was similar for vildagliptin versus combined active and placebo comparators [Mantel&ndash;Haenszel risk ratio 0.84 (95% confidence interval 0.63-1.12)]. In total, 99 out of 8956 patients reported an event in the vildagliptin group vs 91 out of 6061 patients in the comparator group.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Table 8 Key efficacy results of vildagliptin in placebo-controlled monotherapy trials&nbsp; and in add-on combination therapy trials (primary efficacy ITT population)</p><p style="margin-left:0cm; margin-right:0cm; text-align:left"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:58.5pt; vertical-align:top; width:126.85pt"><p style="margin-right:16.9pt; text-align:left"><strong>Monotherapy placebo controlled studies</strong></p></td><td style="border-color:black; height:58.5pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; margin-right:41.55pt; text-align:left"><strong>Mean baseline HbA<sub>1c</sub> (%)</strong></p></td><td style="border-color:black; height:58.5pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.55pt; margin-right:2.85pt; text-align:left"><strong>Mean change from baseline in HbA<sub>1c</sub> (%) at week 24</strong></p></td><td style="border-color:black; height:58.5pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; margin-right:4.85pt; text-align:left"><strong>Placebo-corrected mean change in HbA<sub>1c</sub> (%) at week 24 (95%CI)</strong></p></td></tr><tr><td style="border-color:black; height:44.95pt; vertical-align:top; width:126.85pt"><p style="text-align:left">Study 2301:</p><p style="margin-left:1.5pt; margin-right:27.85pt; text-align:left">Vildagliptin 50 mg twice daily (N=90)</p></td><td style="height:44.95pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; text-align:left">8.6</p></td><td style="height:44.95pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.55pt; text-align:left">-0.8</p></td><td style="height:44.95pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; text-align:left">-0.5* (-0.8, -0.1)</p></td></tr><tr><td style="border-color:black; height:44.5pt; vertical-align:top; width:126.85pt"><p style="text-align:left">Study 2384:</p><p style="margin-left:1.5pt; margin-right:27.85pt; text-align:left">Vildagliptin 50 mg twice daily (N=79)</p></td><td style="height:44.5pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; text-align:left">8.4</p></td><td style="height:44.5pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.55pt; text-align:left">-0.7</p></td><td style="height:44.5pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; text-align:left">-0.7* (-1.1, -0.4)</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:126.85pt"><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p></td><td style="height:17.25pt; vertical-align:top; width:126.75pt"><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p></td><td style="height:17.25pt; vertical-align:top; width:253.6pt" colspan="2"><p style="margin-left:1.55pt; margin-right:0cm; text-align:left">* p&lt; 0.05 for comparison versus placebo</p></td></tr><tr><td style="border-color:black; height:17.25pt; vertical-align:top; width:507.2pt" colspan="4"><p style="text-align:left"><strong>Add-on </strong>/ <strong>Combination studies</strong></p></td></tr><tr><td style="border-color:black; height:44.35pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.5pt; margin-right:2.05pt; text-align:left">Vildagliptin 50 mg twice daily + metformin (N=143)</p></td><td style="height:44.35pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">8.4</p></td><td style="height:44.35pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.55pt; margin-right:0cm; text-align:left">-0.9</p></td><td style="height:44.35pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">-1.1* (-1.4, -0.8)</p></td></tr></tbody></table><p style="text-align:left">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:30.8pt; vertical-align:top; width:126.85pt"><p style="text-align:left">Vildagliptin 50 mg daily</p><p style="text-align:left">+ glimepiride (N=132)</p></td><td style="border-color:black; height:30.8pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; text-align:left">8.5</p></td><td style="border-color:black; height:30.8pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.55pt; text-align:left">-0.6</p></td><td style="border-color:black; height:30.8pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; text-align:left">-0.6* (-0.9, -0.4)</p></td></tr><tr><td style="border-color:black; height:44.95pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.5pt; margin-right:12.5pt; text-align:left">Vildagliptin 50 mg twice daily + pioglitazone (N=136)</p></td><td style="height:44.95pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">8.7</p></td><td style="height:44.95pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.55pt; margin-right:0cm; text-align:left">-1.0</p></td><td style="height:44.95pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; margin-right:0cm; text-align:left">-0.7* (-0.9, -0.4)</p></td></tr><tr><td style="border-color:black; height:44.95pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.5pt; margin-right:2.05pt; text-align:left">Vildagliptin 50 mg twice daily + metformin</p><p style="text-align:left">+ glimepiride (N=152)</p></td><td style="height:44.95pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; text-align:left">8.8</p></td><td style="height:44.95pt; vertical-align:top; width:126.85pt"><p style="margin-left:1.55pt; text-align:left">-1.0</p></td><td style="height:44.95pt; vertical-align:top; width:126.75pt"><p style="margin-left:1.4pt; text-align:left">-0.8* (-1.0, -0.5)</p></td></tr><tr><td style="border-color:black; height:30.8pt; vertical-align:top; width:126.85pt"><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p></td><td style="height:30.8pt; vertical-align:top; width:126.75pt"><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p></td><td style="height:30.8pt; vertical-align:top; width:253.6pt" colspan="2"><p style="margin-left:1.55pt; text-align:left">* p&lt; 0.05 for comparison versus placebo + comparator</p></td></tr></tbody></table><p style="margin-left:33.65pt; text-align:left"><strong><u>Paediatric population</u></strong></p><p style="margin-right:42.55pt; text-align:left">The European Medicines Agency has waived the obligation to submit the results of studies with vildagliptin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left"><!--[endif]--><u>Absorption</u></p><p style="margin-right:23.95pt; text-align:left">Following oral administration in the fasting state, vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1.7 hours. Food slightly delays the time to peak plasma concentration to 2.5 hours, but does not alter the overall exposure (AUC). Administration of vildagliptin with food resulted in a decreased C<sub>max</sub> (19%). However, the magnitude of change is not clinically significant, so that Vildagliptin can be given with or without food. The absolute bioavailability is 85%.</p><p style="text-align:left"><u>Distribution</u></p><p style="margin-right:23.75pt; text-align:left">The plasma protein binding of vildagliptin is low (9.3%) and vildagliptin distributes equally between plasma and red blood cells. The mean volume of distribution of vildagliptin at steady- state after intravenous administration (V<sub>ss</sub>) is 71 litres, suggesting extravascular distribution.</p><p style="text-align:left"><u>Biotransformation</u></p><p style="margin-right:23.8pt; text-align:left">Metabolism is the major elimination pathway for vildagliptin in humans, accounting for 69% of the dose. The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano moiety, accounting for 57% of the dose, followed by the glucuronide (BQS867) and the amide hydrolysis products (4% of dose). In vitro data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of vildagliptin to its major inactive metabolite, LAY151. DPP-4 contributes partially to the hydrolysis of vildagliptin based on an <em>in vivo </em>study using DPP-4 deficient rats. Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent. Accordingly, the metabolic clearance of vildagliptin is not anticipated to be affected by co-medications that are CYP 450 inhibitors and/or inducers. <em>In vitro </em>studies demonstrated that vildagliptin does not inhibit/induce CYP 450 enzymes. Therefore, vildagliptin is not likely to affect metabolic clearance of co-medications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5.</p><p style="text-align:left"><u>Elimination</u></p><p style="margin-right:23.7pt; text-align:left">Following oral administration of [<sup>14</sup>C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose is recovered in the faeces. Renal excretion of the unchanged vildagliptin accounted for 23% of the dose after oral administration. After</p><p style="text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:23.8pt; text-align:left">intravenous administration to healthy subjects, the total plasma and renal clearances of vildagliptin are 41 and 13 l/h, respectively. The mean elimination half-life after intravenous administration is approximately 2 hours. The elimination half-life after oral administration is approximately 3 hours.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left"><u>Linearity / non-linearity</u></p><p style="margin-right:24.3pt; text-align:left">The C<sub>max</sub> for vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in an approximately dose proportional manner over the therapeutic dose range.</p><p style="text-align:left"><u>Characteristics in specific groups of patients</u></p><p style="text-align:left">Gender</p><p style="margin-right:24.1pt; text-align:left">No clinically relevant differences in the pharmacokinetics of vildagliptin were observed between male and female healthy subjects within a wide range of age and body mass index (BMI). DPP-4 inhibition by vildagliptin is not affected by gender.</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Elderly</p><p style="margin-right:24pt; text-align:left">In healthy elderly subjects (&ge; 70 years), the overall exposure of vildagliptin (100 mg once daily) was increased by 32%, with an 18% increase in peak plasma concentration as compared to young healthy subjects (18-40 years). These changes are, however, not considered to be clinically relevant. DPP-4 inhibition by vildagliptin is not affected by age.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Hepatic impairment</p><p style="margin-right:23.75pt; text-align:left">The effect of impaired hepatic function on the pharmacokinetics of vildagliptin was studied in patients with mild, moderate and severe hepatic impairment based on the Child-Pugh scores (ranging from 6 for mild to 12 for severe) in comparison with healthy subjects. The exposure to vildagliptin after a single dose in patients with mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to vildagliptin for patients with severe impairment was increased by 22%. The maximum change (increase or decrease) in the exposure to vildagliptin is ~30%, which is not considered to be clinically relevant. There was no correlation between the severity of the hepatic disease and changes in the exposure to vildagliptin.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Renal impairment</p><p style="margin-right:23.8pt; text-align:left">A multiple-dose, open-label trial was conducted to evaluate the pharmacokinetics of the lower therapeutic dose of vildagliptin (50 mg once daily) in patients with varying degrees of chronic renal impairment defined by creatinine clearance (mild: 50 to &lt;80 ml/min, moderate: 30 to &lt;50 ml/min and severe: &lt;30 ml/min) compared to normal healthy control subjects.</p><p style="margin-left:0cm; text-align:left">&nbsp;</p><p style="margin-right:23.75pt; text-align:left">Vildagliptin AUC increased on average 1.4, 1.7 and 2-fold in patients with mild, moderate and severe renal impairment, respectively, compared to normal healthy subjects. AUC of the metabolites LAY151 and BQS867 increased on average about 1.5, 3 and 7-fold in patients with mild, moderate and severe renal impairment, respectively. Limited data from patients with end stage renal disease (ESRD) indicate that vildagliptin exposure is similar to that in patients with severe renal impairment. LAY151 concentrations were approximately 2-3-fold higher than in patients with severe renal impairment.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:33.65pt; margin-right:23.7pt; text-align:left">Vildagliptin was removed by haemodialysis to a limited extent (3% over a 3-4 hour haemodialysis session starting 4 hours post dose).</p><p style="margin-left:0cm; margin-right:0cm; text-align:left">&nbsp;</p><p style="text-align:left">Ethnic group</p><p style="margin-right:24.4pt; text-align:left">Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:23.85pt; text-align:left">Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7-fold human exposure based on C<sub>max</sub>).</p><p style="margin-left:33.65pt; margin-right:23.75pt; text-align:left">Accumulation of foamy alveolar macrophages in the lung was observed in rats and mice. The no-effect dose in rats was 25 mg/kg (5-fold human exposure based on AUC) and in mice 750 mg/kg (142-fold human exposure).</p><p style="margin-right:23.9pt; text-align:left">Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhea and, at higher doses, faecal blood were observed in dogs. A no-effect level was not established.</p><p style="text-align:left">Vildagliptin was not mutagenic in conventional <em>in vitro </em>and <em>in vivo </em>tests for genotoxicity.</p><p style="margin-left:33.65pt; margin-right:23.75pt; text-align:left">A fertility and early embryonic development study in rats revealed no evidence of impaired fertility, reproductive performance or early embryonic development due to vildagliptin. Embryo-foetal toxicity was evaluated in rats and rabbits. An increased incidence of wavy ribs was observed in rats in association with reduced maternal body weight parameters, with a no- effect dose of 75 mg/kg (10-fold human exposure). In rabbits, decreased foetal weight and skeletal variations indicative of developmental delays were noted only in the presence of severe maternal toxicity, with a no-effect dose of 50 mg/kg (9-fold human exposure). A pre- and postnatal development study was performed in rats. Findings were only observed in association with maternal toxicity at &ge; 150 mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation.</p><p style="margin-right:23.6pt; text-align:left">A two-year carcinogenicity study was conducted in rats at oral doses up to 900 mg/kg (approximately 200 times human exposure at the maximum recommended dose). No increases in tumour incidence attributable to vildagliptin were observed. Another two-year carcinogenicity study was conducted in mice at oral doses up to 1,000 mg/kg. An increased incidence of mammary adenocarcinomas and haemangiosarcomas was observed with a no- effect dose of 500 mg/kg (59-fold human exposure) and 100 mg/kg (16-fold human exposure), respectively. The increased incidence of these tumours in mice is considered not to represent a significant risk to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of tumours only in one species and the high systemic exposure ratios at which tumours were observed.</p><p style="margin-right:23.7pt; text-align:left">In a 13-week toxicology study in cynomolgus monkeys, skin lesions have been recorded at doses &ge; 5 mg/kg/day. These were consistently located on the extremities (hands, feet, ears and tail). At 5 mg/kg/day (approximately equivalent to human AUC exposure at the 100 mg dose), only blisters were observed. They were reversible despite continued treatment and were not associated with histopathological abnormalities. Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses &ge; 20 mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose). Necrotic lesions of the tail were observed at &ge; 80 mg/kg/day. Skin lesions were not reversible in the monkeys treated at 160 mg/kg/day during a 4-week recovery period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Anhydrous lactose, microcrystalline cellulose PH 112, sodium starch glycolate, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Store below 30&deg;C.</p><p style="text-align:left">Store in the original package in order to protect from moisture</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.65pt; text-align:left"><strong>Viltin<sup>&reg;</sup> 50 mg Tablets </strong>are packed in Alu/Alu blister, intended for oral use.</p><p style="margin-left:33.65pt; text-align:left">Pack size: 7 tablets in Alu/Alu blister. 4 blisters/pack. 10 tablets in Alu/Alu blister. 6 blisters/pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharma International Company Amman - Jordan
Tel: 00962-6-5158890 / 5157893
Fax: 00962-6-5154753
email: marketing@pic-jo.com


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>